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Abstract 
 
Timothy Myers: Regulation of TACE-Dependent TGF-α Shedding  
(Under the direction of David C. Lee) 
 
   The ErbB signaling network regulates many critical biological processes.  This network 
consists of Epidermal Growth Factor Receptor (EGFR) and three related receptors and a 
superfamily of growth factor ligands.  Signaling is initiated when EGF-like polypeptide 
ligands bind to EGFR, ErbB3 or ErbB4, causing receptor homo- or heterodimerization 
between the four related receptor tyrosine kinases, including the orphan receptor ErbB2.  
The EGF-like family of growth factors include: epidermal growth factor (EGF), transforming 
growth factor-α (TGF-α), amphiregulin (AR), heparin binding-epidermal growth factor (HB-
EGF) betacellulin (BTC), epiregulin (EPR), epigen (EPI).  The growth factors binding to ErbB 
receptors are produced as membrane anchored precursors that can be proteolytically 
cleaved in the extracellular juxtamembrane domain to release mature, soluble ligands, in a 
process termed ectodomain shedding.  Metalloproteases, in particular the family of 
disintegrin and metalloproteases (ADAMs) have been identified as the proteases 
responsible for the shedding of diverse cell surface proteins.  Efforts to understand the 
regulation of growth factor shedding led to the discovery of ADAM17, or tumor necrosis 
factor-α converting enzyme (TACE), as the major sheddase for the ErbB ligands.  Evidence 
came from biochemical and in vivo studies, including mice lacking functional TACE due to a 
deletion in the metalloprotease domain.  Homozygous TACE-deficient animals displayed 
perinatal lethality similar to EGFR-null mice and revealed subtle phenotypes that mimicked 
single growth factor null mice such as delayed eyelid closure like TGF-α deficient mice, 
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heart and lung defects seen in the absence of HB-EGF and mammary gland development 
issues found in AR null creatures.  Despite the recognition of a key role for TACE in 
development, understanding of the regulation mechanisms are incomplete.  Several findings 
point to a role for MAPK pathways, non-receptor tyrosine kinases, calcium and calcium-
dependent kinases and reactive oxygen species.  The work described here identifies a 
pathway initiated by ATP binding to the P2Y family of GPCRs that mediates TACE-
dependent TGF-α shedding and concomitant EGFR activation.  Transactivation offers a 
physiologically relevant pathway to examine the mechanism of TACE regulation, which I use 
to identify mitochondria as a source of the key signaling intermediate in TACE activation, 
reactive oxygen species. 
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Chapter 1 
 
 
 
 
Introduction 
 
   Activation of ErbB receptors by G-protein coupled receptors (GPCRs) regulates many 
essential biological processes and could play an important role in cancer progression and 
cardiovascular disease.  The focus of this work is on the regulation of cleavage of the ErbB 
receptor activating growth factor ligand, TGF-α.  TGF-α is cleaved from the extracellular 
segment of a cell surface precursor, proTGF-α, in a process termed ectodomain shedding.  
The disintegrin and metalloprotease (ADAM) proteins, and in particular ADAM17/TACE, are 
established mediators of this TGF-α shedding event.  Shedding can be stimulated by signals 
from GPCRs, leading to the activation of the ErbB receptor, EGFR.  This process, known as 
transactivation, allows us to examine regulatory signals and proteins that can control TACE-
dependent TGF-α shedding. 
 
The ErbB Signaling Network 
   Epidermal Growth Factor Receptor (EGFR/ErbB1) is the prototype of a family of receptors 
whose imperative functions regulate cell activities such as adhesion, differentiation, 
proliferation and survival (1-3).  The ErbB superfamily is made up of four related, type-I 
receptor tyrosine kinases and their polypeptide growth factor ligands.  Homologues of these 
receptors and growth factors are found throughout evolution (4).  Highlighting the 
importance of this signaling network are key physiological roles in development and 
maintenance of the cardiovascular, respiratory and gastrointestinal systems (1).  Moreover, 
several of these network components act as oncogenes in many different types of cancer 
(5,6).  EGFR and ErbB2 are promising clinical targets and growth factor ligands are 
overexpressed in many neoplastic tissues.  Thus, these receptors and their ligands are 
essential not only for normal development and adult cell maintenance, but are also key 
targets in the fight against malignant cancer. 
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The ErbB Receptors 
   The four related receptors of the ErbB family include:  EGFR (ErbB1, mouse/HER1, 
human), ErbB2 (HER2/neu), ErbB3 (HER3) and ErbB4 (HER4) (2,7).  Each contains an 
ectodomain consisting of two cysteine-rich domains combined with two unique domains that 
function together as ligand binding regions.  A single transmembrane domain connects the 
extracellular portion of the receptor to a cytoplasmic tail containing an intrinsic tyrosine 
kinase domain.  The cytoplasmic region also contains numerous tyrosines and docking 
motifs that allow signaling molecules to bind when phosphorylated.  ErbB3 lacks the active 
kinase domain, but maintains its signaling motifs and function through cross-phosphorylation 
in heterodimers with the other ErbB receptors. 
   ErbB receptor signaling requires the cooperation of the entire protein.  Receptor activation 
occurs upon ligand binding which leads to dimerization with either the same receptor family 
member (homodimerization), or another ErbB receptor (heterodimerization) (8).  
Dimerization occurs after ligand binding to the extracellular domain causing a 
conformational change that exposes a bridging arm made up mostly of the first cysteine-rich 
domain; once exposed this arm interacts with the arm of another receptor (9).  ErbB2, which 
does not have a known ligand, but imparts higher ligand affinities and longer, more robust 
signaling activities with heteromeric partners, appears to adopt this pro-interaction 
conformation constitutively based on the crystal structure of the extracellular domain (10).  
The ErbB2 receptor-interaction arm is unique in containing a negative electrostatic charge 
that deters ErbB2 homodimers, but strengthens heterodimer interactions, thus helping to 
explain why ErbB2 is the preferred heterodimer partner.  The solution of the ErbB2 crystal 
structure also clarified why there may be no binding ligand for ErbB2, as key ligand binding 
residues differ from those of the other ErbB receptors and a smaller, enclosed binding 
pocket impedes ligand association (10).  The extracellular ligand interaction and subsequent 
domain rearrangement of ErbB1, ErbB3 and ErbB4 receptors is also believed to allow for a 
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conformational change of the intracellular domain that triggers auto- and trans- 
phosphorylation of the cytoplasmic tyrosine kinase domain activation loop based on the well 
studied prototypes of non-receptor protein kinases (11).  The kinase domain can then 
phosphorylate tyrosines on either receptor (auto- or trans- phosphorylation) which interact 
with signaling proteins containing Src homology 2 (SH2) or phosphorylated tyrosine binding 
(PTB) motifs. 
   The SH2 and PTB domain-containing signaling proteins link the receptors to canonical 
signaling pathways.  Proteins that contain SH2 and PTB domains include adaptor proteins 
such as, Shc, Crk, Grb2, Grb7, Gab1, non-receptor src-like kinases Src, the common 
signaling protein PI3K and tyrosine phosphatases like SHP1 and SHP2 (12,13).  Which 
signaling proteins bind and are activated depends on the receptor pair involved, since each 
ErbB receptor has overlapping as well as distinct docking motifs; it also depends on the 
pattern of tyrosine phosphorylation, which specifies the motifs available as docking sites 
(14,15).  Initiation of biological effects is accomplished mainly through two major signaling 
pathways: Ras-Raf-MAPK and PI3K-Akt (1,16).  The Mitogenic-Activated Protein Kinase 
(MAPK) pathways are targeted by every ErbB receptor.  As with all ErbB initiated pathways, 
binding and phosphorylation of adaptor proteins leads to larger transient complexes that 
allow activation of more downstream signaling molecules.  Activation of signaling molecules 
is accomplished by phosphorylation cascades that activate downstream kinases before 
ultimately targeting transcription factors for the alteration of gene expression patterns.  The 
other major pathway, PI3K-Akt, is vital due its influence on not only gene expression 
patterns, but also cell survival and proliferation signals (17).  PI3K can interact directly with 
the phosphorylated ErbB3/4 cytoplasmic tail via its p85 regulatory subunit, while adaptor 
proteins are required in the case of EGFR and ErbB2 (18).  Growing evidence suggests that 
it is this activation of the PI3K pathway, required for tumorigenesis, which makes the EGFR 
family of receptors potent oncogenes and thus important targets for cancer therapies. 
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ErbB Ligands 
   Under basal conditions receptors require ligands to initiate efficient dimerization.  The 
ligands, like their receptors, are members of a family, in this case polypeptide growth 
factors, that share similar structure and functions.  The Epidermal Growth Factor (EGF)-like 
family is named after the first identified member, EGF (19).  There are seven members of 
this family that can be further divided into two groups based on their binding specificity.  
Group 1 consists of EGF, Transforming Growth Factor-α (TGF-α), Amphiregulin (AR) and 
Epigen (EPI); this group binds with high affinity to only EGFR.  Group 2 is made up of 
Betacelllulin (BTC), Heparin Binding-Epidermal Growth Factor (HB-EGF) and Epiregulin 
(EPR); members of this group interact strongly with both EGFR and ErbB4.  A third group 
consists of the related growth factors termed neuregulins (NRG), which are ligands for 
ErbB3 and ErbB4.  Neuregulins are related to the other EGF family growth factors by their 
EGF-like domain and receptor preferences, but considered unique due to their function in 
neuronal development and the use of alternative splicing to generate up to 14 different 
isoforms, including some that lack a cytoplasmic domain (20).   
   EGF-like growth factor family members in groups 1 and 2 are all produced as membrane 
anchored precursors with similar structure (Figure 1.1) (19).  The signal peptide and pro-
domain are followed by an N-terminal extension of variable length, except in the case of 
TGF-α and EPI, which have no intervening sequence.  Prior to the EGF-like peptide, which 
forms a three-loop structure due to disulfide bonds between six cysteines, is the receptor-
binding motif of the protein.  The cysteines are embedded in a consensus sequence that 
allows for proper folding of the mature, receptor binding region.  This EGF-like peptide, 
which sits a short distance from the membrane, can be proteolytically released from its 
transmembrane tail by cleavage in the juxtamembrane region to produce a mature, soluble 
peptide that is necessary and sufficient to interact with receptor.  The N-terminal extension 
can also be proteolytically removed in a rapid cell surface event, though the identity and 
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regulation of this protease is unclear (21,22).  The ectodomain of all family members 
appears to be highly glycosylated leading to variably sized precursor forms whose effect on 
function is not understood.  The single-spanning transmembrane domain is followed by a 
cytoplasmic tail of variable length depending on the growth factor.  The cytoplasmic tail of 
the precursor, while not necessary for receptor activation, may play a role in growth factor 
maturation and proper localization (23).   
   While all family members act as potent growth signals and can induce transformed growth, 
important distinctions exist (19).  Despite the overall structure and EGF-like motif, minimal 
sequence homology is present among the ligands and the N-terminal pro-region and 
cytoplasmic domains often vary widely in their length and function (24).  Lastly, while there 
appears to be some overlap in biological activity, each family member potentially may have 
distinct roles as well.      
   The precursor to the first growth factor discovered, proEGF, is a large protein with a 
greatly extended N-terminal sequence compared to the other growth factors (19).  This 
extension is made up of eight separate EGF-like motifs in addition to the bona fide receptor 
binding EGF-like sequence (Figure 1.1).  As with most family members, EGF is broadly 
expressed throughout life and a long list of functions has been attributed to this growth 
factor.  EGF knockout mice display no overt phenotype (25), likely owing to redundancy of 
other EGF-peptides.  However, EGF transgenic mice showed stunted growth and bone 
deformities, but no increase in tumorigenesis (26).  As noted previously, EGF has a high 
affinity for EGFR and preferentially induces EGFR homodimers and EGFR:ErbB2 
heterodimers, though there is now evidence for a low affinity interaction with ErbB3 (27,28). 
   Other type I EGF-like growth factors are TGF-α, AR and EPI.  TGF-α is the best studied 
member of the family and possesses several prominent actions.  TGF-α knockout mice are 
viable and fertile, but display epidermal defects including wavy hair and whiskers, abnormal 
patterning of hair follicles and delayed eyelid closure during embryonic development (29).  
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TGF-α transgenic mice revealed that overexpression produced abnormal growth in several 
organs and mammary tumors (30).  Spontaneous, overexpressed AR has also been 
discovered in many malignancies, including those induced by a TGF-α transgenic model in 
the mammary gland (31).  AR is a heparin binding, bifunctional ligand, so described 
because it could inhibit prolifereation of A431 carcinoma cells while stimulating proliferation 
of fibroblasts, through a relatively low affinity interaction with EGFR.  Studies of mice bearing 
a targeted deletion in AR showed a critical role in mammary gland development (25).  Ductal 
outgrowth was impaired in female mice lacking functional AR, hindering the proper quantity 
and quality of milk; this phenotype was further exacerbated when combined with TGF-α and 
EGF deficiencies in triple-null mice.  Epigen is the most recently identified EGFR ligand and 
little is known about its function.  Its low-affinity interaction with EGFR does not rule out 
interaction with other receptor family members, but the higher mitogenic potential than EGF 
with EGFR suggests EPI is compatible with this group of growth factors (32).        
   Group 2 of the EGF-like growth factors (HB-EGF, BTC and EPR) are capable of high 
affinity interactions with both EGFR and ErbB4.  The best studied member of this group, HB-
EGF, requires its heparin binding domain for optimal receptor binding and activity (24).  This 
appears to be due to the availability, presentation and altered binding afforded the mature 
peptide by an interaction with extracellular heparin.  As with all other family members, 
expression is detected throughout mammalian tissues.  HG-EGF knockout mice produced a 
non-Mendelian ratio of genotypes from crosses of HB-EGF heterozygotes with 60% of HB-
EGF-/- homozygotes dying before weaning (33,34).  Survivors were viable and fertile, yet 
contained enlarged hearts with no discernable difference in body weights compared to wild 
type control mice.  Death was likely due to cardio-pulmonary defects, including enlarged 
heart valves from persistent proliferation of mesenchymal cells during valvulogenesis and 
alveoli formation in the lung, likely due to dysregulated BMP signaling (33).  Further 
evidence for the role of HB-EGF in heart development came from Iwamoto et al (34), who 
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confirmed the above findings and uncovered enlarged ventricular chambers and reduced 
cardiovascular function in their version of HB-EGF-null mice.  Upregulation of HB-EGF 
expression occurs at sites of injury, suggesting a role in wound healing (24).  Wound stimuli 
initiate an HB-EGF-shedding response and subsequent EGFR activation leading to 
migration of keratinocytes into the wound site (35).  HB-EGF has also been found to be 
linked to the upregulation of an early immune response in skin wounds (36).  During 
development, HB-EGF may promote implantation and growth of the embryo, as evidenced 
by HB-EGF expression in response to estrogen and progesterone (37), and central nervous 
system maturity due to cell proliferation, motility and survival (38,39).  Finally, HB-EGF 
expression has also been detected in several types of tumors positioning HB-EGF as a 
potentially important EGFR family ligand in cancer (19). 
   Other Group 2 growth factors that share high affinity binding with EGFR and ErbB4 are 
BTC and EPR.  These growth factors can also bind to ErbB3 in ErbB2:ErbB3 heterodimers 
making these pan-ErbB ligands (19).  Both peptides are expressed in many different tissues, 
with enhanced expression in several neoplastic tissues.  BTC knockout mice present no 
overt phenotype indicating overlap of other family growth factors (33).  This redundancy was 
supported when BTC knockout mice were crossed with HB-EGF knockout mice to form the 
double knockouts that exacerbated the HB-EGF heart and mortality phenotype (33).  
Overexpression of BTC by transgenics however, produced early postnatal death and 
reduced body weight.  Mortality was most likely due to pulmonary defects, such as 
thickened alveolar septa, accumulation of macrophages and alveolar hemorrhaging (40).  
EPR, like AR, is a bifunctional ligand that can stimulate and inhibit growth in different cell 
lines.  EPR-null mice reveal no phenotype, but are vulnerable to cancer predisposing 
intestinal damage (19).  No transgenic models yet exist. 
   The members of the EGF-like family of growth factors are similar, yet different.  
Structurally, the growth factors are almost identical, sharing a conserved protein fold 
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important for receptor binding.  However, there is very little sequence homology and the 
precursor proteins can vary widely in size.  In terms of signaling, there does appear to be 
some redundancy among growth factors, but individual knockout models also reveal 
independent activities that cannot be accounted for by related growth factor family 
members.  Almost, all family members potentially function in transformed growth of 
neoplastic tissue making them important therapeutic targets for several types of human 
cancer.  The details of signaling specificity must be elucidated to take advantage of these 
potent signaling ligands. 
 
ErbB Signaling Characteristics 
   As presented above, the ErbB family of receptors and ligands play fundamental roles in 
development, growth and homeostasis in many different species as seen by lethality in mice 
lacking the ErbB receptors and disruption or delay of development of several tissues with 
the loss of growth factors.  Genetically engineered models lacking growth factor activity 
indicates redundancy of the growth factor functions, underscoring the importance of these 
systems.  Overlapping functions raise the question of how specificity is generated within the 
numerous and sometimes opposing responses that define a network.  The ligands and 
receptors each offer characteristics with which potential degrees of specificity can be 
defined.   
   A central purpose of the ligands appears to be influencing the selection of dimer partners.  
While ErbB2 is always a possible partner, the ligands influence which of the remaining 
receptors are available for dimerization (41).  This is important because downstream signals 
are determined by the receptor pairing due to the differences in signaling motifs present on 
each receptor and the affect of trans-phosphorylation on selection of targeted tyrosines (42).  
Ligand discrimination by the receptor dimers would also allow ligands to directly affect the 
tyrosine phosphorylation pattern of the receptors (43).  The first evidence of ligand 
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differentiation was reported when EGF- and BTC-induced phosphorylation patterns were 
compared in mouse cells expressing EGFR or ErbB4 (44).  The strongest evidence was 
seen using ErbB4 interactions with BTC NRG1β, NRG2β and NRG3.  While bulk 
phosphorylation of the receptor cytoplasmic domain was increased with each ligand, 
different consequences were detected that affected proliferation and migration of a human T 
cell line, CEM, depending on the growth factor.  Closer inspection of the phosphorylated 
tyrosines revealed a consistently unique pattern following stimulation with each ligand (45).   
   Another characteristic of ligands that affects signal specificity is binding affinity.  The 
strength and interval of the interaction could have a profound effect on the final genetic 
program initiated by receptor signaling, as lower affinity ligands delay degradation of EGFR 
(46).  Other features that also could affect ligand affinity include the N-terminal extension on 
some growth factors, as seen with the heparin binding domains of HB-EGF and AR, and 
distinctions in signaling between soluble and membrane anchored ligands (19).  Though 
genetic evidence suggests the soluble growth factor is the essential form (33,47), signaling 
by membrane anchored TGF-α has been described (48,49).  Lastly, the strength of the 
ligand:receptor interaction varies under diverse pH conditions for each ligand.  For instance, 
TGF-α dissociates at endosomal pH while EGF, and to an even greater extent BTC, can 
withstand lysosomal pH ranges (50).  This allows longer signal duration and possibly diverse 
signals, since EGFR has been shown to transmit distinct signals when localized to 
endosomes (51). 
   Along with specific docking sites, receptors have additional characteristics that can be 
utilized in specifying signal pathways.  Localization of receptors in polarized cells, in 
membrane microdomains and to internal vesicles have all been demonstrated to influence 
potential signaling attributes of the ErbB receptors.  As mentioned, EGFR signaling from 
endosomes is distinct from that initiated on the surface.  Neuregulin induced expression of 
acetylcholine receptor requires MAPK signaling that only occurs following receptor 
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internalization and signaling from a clathrin-coated endocytic vesicle (52).  Additionally, 
phospholipase-Cγ signaling from EGFR does not require endocytosis, while sustained EGF-
induced MAPK signaling does, due to the necessary recruitment of scaffolding proteins by 
endosomal adaptor proteins (51).  EGFR signaling based on membrane sorting has also 
been established.  When channeled to the apical membrane of polarized epithelial cells 
EGFR activated SHC-dependent pathways and increased β-catenin phosphorylation, 
whereas on the basolateral surface, SHC pathways were combined with phospholipase-Cγ 
and focal adhesion kinase activity (53,54).  Detergent-resistant membrane microdomains, 
called rafts, have been shown to contain various ErbB receptors prior to ligand binding and 
activation.  Also, positioning in rafts prior to activation could influence dimer partners, 
depending on which receptors are present (41).  Rafts could also function in assembling 
signaling complexes on activated receptors by enriching for particular signaling proteins, 
such as H-Ras on the cytoplasmic side of the raft (55).  Beyond localization, extracellular 
interacting proteins could function in facilitating or obstructing ligand binding (43), while the 
carbohydrate modifications could also function in spatial and temporal alterations of ligand 
binding (41).  Finally, recruitment of phosphatases to the receptor cytoplasmic region can 
influence the phosphorylation pattern and thus the duration and nature of signaling (56).  
Clearly there is much more work to be done in order to validate these potential layers of 
specificity. 
 
The ADAM Family Proteins   
   Soluble EGF-like growth factors can mediate unique activities compared to anchored 
growth factors and soluble ligands are vital to proper development.  Identification of the 
protease(s) responsible for cleavage is therefore critical to the understanding of regulation of 
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EGFR signaling.  ADAM family proteases have since emerged as the chief enzymes 
responsible for cleavage of the EGF-like growth factors.   
 
ADAM Structure 
   ADAM is short for A Disintegrin And Metalloprotease which describes the key domains of 
these family members that belong to the adamalysin group of the metzincin zinc protease 
superfamily (Figure 1.2).  ADAMs are closely related to the snake venom metalloproteases 
(SVMP) in their shared extracellular domain arrangement and similar metalloprotease 
catalytic domain structure (57,58).  Along with these features, these type I transmembrane 
glycoproteins are known for their conserved domain sequence: pro-, metalloprotease, 
disintegrin, a cysteine-rich juxtamembrane, a transmembrane and cytoplasmic domain.  
From the 40 family members currently recognized across all species, crucial functions have 
been identified in fertilization, neurogenesis, angiogenesis and ectodomain shedding of 
membrane anchored proteins (59,60).  ADAM proteins can be generally grouped into two 
categories: testis specific and those that are more broadly expressed.  In humans, the 
predominantly testis specific ADAMs are 2, 3, 6, 18, 20, 21, 29, 30, and 32.  The remaining 
are somatically expressed and of these 8-10, 12, 15, 17, 19, 28 and 33 (predicted) are 
thought to be catalytically active (61).  While activities and relevance have been shown for 
ADAMs without protease activity, especially concerning cell adhesion in spermatogenesis 
and fertilization, I will focus only on the protease active proteins.  It is from these, specifically 
ADAMs 9, 10, 12, 15, 17 and 19, that potential sheddases for the ErbB ligands emerge.      
   The prodomain is a ~200 amino acid peptide that acts as an autoinhibitor of the 
metalloprotease domain to dampen protease function during transport through the cell.  
Most ADAMs utilize a “cysteine switch” mechanism, whereby a conserved cysteine in the 
prodomain helps to coordinate the essential catalytic zinc atom, thus inactivating the 
protease.  A similar mechanism has been described for matrix metalloproteases (MMP) (61).  
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Alternatively, ADAM10 and 17 employ the cysteine switch only to protect against premature 
degradation (62).  Instead, with these ADAMs, the protease is potently restrained when the 
cysteine-rich domain (CRD) helps position the prodomain, thus altering the native 
conformation of the metalloprotease domain (63).  Prior to surface localization, all ADAMs 
are cleaved by proprotein convertases to detach the prodomain from the mature ADAM.  
Serine/Threonine proteases furin and PC7 have been identified as the enzymes responsible 
for this action on ADAM10 and 17, and most likely, for all other ADAMs (64-66), except 
ADAM28 which appears to autocatalytically remove its prodomain (67).  Furin cleavage 
takes place in the Trans to Late Golgi Network, though the prodomain may remain bound in 
the metalloprotease substrate binding site until delivery to the surface, as the prodomain 
also acts as a chaperone for folding and secretion (62). 
   The metalloprotease domain directly follows the prodomain.  Highlighting the dual 
behavior of some ADAMs is the fact that some lack functional protease domains.  Twenty-
five ADAMs are thought to be active proteases based on analysis of this domain, though a 
proven protease activity has only been shown for half of these.  Activity is thought to 
correlate with the presence of a highly conserved consensus sequence found in all active 
proteases of the metzincin family: His-Glu-X-X-His-X-X-Gly-X-X-His.  The three conserved 
histidine residues position the metal ion, usually zinc, which in turn coordinates the water 
molecules to allow hydrolytic proteolysis.  Use of in vitro peptide assays to test individual 
domains of ADAM17 have established that the metalloprotease domain alone contains the 
necessary sequence for catalytic activity, though other domains may impart regulation 
(68,69).  The metalloprotease domain is also subject to many active site binding inhibitors 
as a form of regulation.  The endogenous tissue inhibitors of metalloprotease are broad 
proteinacious inhibitors of metalloproteases that block substrate binding in the catalytic 
pocket (70,71).  Related to this, chemically synthesized inhibitors that are aimed at specific 
ADAM active sites have also been under development due to the role of ADAMs in disease 
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progression.  The crystal structure for several active proteases in association with these 
inhibitors (58,72) will allow better design of the next generation of inhibitors (73,74).     
   The disintegrin domain was first identified in SVMPs that interact with platelet integrins to 
inhibit clotting in the victim.  Integrin interactions have also been associated with this domain 
in ADAMs, yet the functional links have only recently been addressed (Table 1.1).  Human 
ADAM15, which is the only known ADAM with the consensus integrin binding sequence Arg-
Gly-Asp (RGD), can interact with the integrin receptors αVβ3 and α5β1 through the RGD 
sequence (75,76).  The integrin α9β1 is often found in association with ADAMs, but 
associates independent of the RGD sequence.  Instead, α9β1 requires the sequence 
RXXXXXXDLPEF found in the disintegrin domain of all interacting partners (77).  
Functionally, ADAM:integrin associations appear able to affect cell migration, both positively 
and negatively (78).  The TACE:α5β1 interaction is found in focal adhesions and leading 
edges of CHO and HeLa cells and inhibits cell migration in wounding assays (79,80).  
Likewise ADAM12 appears to impair normal integrin function leading to decreased cell 
adhesion of adipocytes by α4β1 (81), and ADAM15 overexpression reduces ovarian 
carcinoma cell adhesion to vitronectin through αVβ3 (76).  ADAM9 appears to be a promoter 
of cell invasion, since α6β1-expressing cells displays enhanced migration ability on ADAM9 
coated plates versus control plates (76) and soluble ADAM9 provokes invasion of numerous 
cell lines through α6β4 and α2β1 (82).  It appears as though ADAM, integrin interactions can 
disrupt the conventional integrin interactions leading to altered signaling and function.  
However, the majority of these studies were done using recombinant proteins, thus further 
investigation of the endogenous functions and interactions will be required to verify the 
validity of these findings.   
   Thus far the cysteine-rich domain (CRD) has only been found to complement the other 
domains.  Beyond coordination of the prodomain as an inhibitor of metalloprotease activity, 
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the ADAM12 disintegrin/CRD promotes adhesion between fibroblasts and myoblasts 
dependent on the disulfide bonds formed between cysteines (83).  Coated culture dishes of 
ADAM12 CRD led to adhesion and cell migration due to an interaction with the cell surface 
adhesion molecule snydecan-4.  In the absence of this interaction cells did not adhere to the 
plate, suggesting the CRD may have an independent function in some ADAMs (84).  Other 
ADAM family members offer examples of non-adhesion based interactions and will be 
covered below.  In summary, these domains have been determined, thus far, to regulate the 
binding capabilities of the extracellular region. 
   Finally, the cytoplasmic domain varies in both length, sequence and function among the 
family members.  A regulatory role for the cytoplasmic domain is suggested by the presence 
of potential binding motifs for signaling molecules.  Most commonly they are Pro-X-X-Pro, 
that are considered SH2 or 3 binding motifs for signaling proteins.  Interactions of signaling 
molecules with the cytoplasmic domains of ADAMs 9, 10, 12, 13, 15 and 17 have been 
reported, though limited functional studies have been performed and no physiological roles 
for these interactions have been established (Table 1.2).  There are also several examples 
of induced phosphorylation of this domain.  ADAM9 was phosphorylated following phorbol 
12-myristate 13-acetate (PMA) stimulation (85), while Erk-dependent phosphorylation of 
ADAM17 in HeLa cells was also induced by PMA and was necessary for TACE surface 
localization (86).  A second article challenged this finding in CHO cells, using a point 
mutation at Thr735 that did not diminish overall TACE phosphorylation levels, suggesting a 
different residue was phosphorylated.  Serum-induced phosphorylation of TACE instead 
targeted Ser819 and was coupled with Ser791 dephosphorylation.  However, this 
phosphorylation had no effect on the metalloprotease activity, as point mutations of these 
serines and a complete cytoplasmic truncation had no effect on TGF-α shedding (87).  This 
is in agreement with Reddy and colleagues, who showed PMA stimulated TNF-α shedding 
was not dependent on the presence of the TACE cytoplasmic domain (88).  The cytoplasmic 
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domain of several other ADAMs is also dispensable for protease function based on cell 
models and in vitro assays.  Recently, ADAM10 was shown to mediate BTC shedding in 
response to calcium induced signals, despite the absence of its cytoplasmic domain (89).  
Evolution also suggests the expendable nature of the cytoplasmic domain.  Naturally 
occurring alternative splice variants of ADAM9 and ADAM12 that are secreted due to 
truncations above the transmembrane domain maintain their protease activity towards 
laminin (82) and insulin-like growth factor binding protein-3 (71), respectively.  Due to their 
low abundance in nature, the requirements and functional consequence of these 
alternatively spliced forms is still in doubt, especially under normal circumstances, as the 
short form of ADAM9 may only be produced in response to aberrant neoplastic signals for 
assistance in cell invasion by sequestering integrin interactions (82).  Thus, while not 
necessary, the cytoplasmic domain may still function in localization, maturation and 
regulation of ADAMs.       
 
 
 
Ectodomain Shedding of ErbB Ligands By ADAMs  
   After the critical discovery of ADAM17 as a TGF-α sheddase, other ADAM family 
members were implicated in cleavage of ErbB ligands.  Overexpression experiments with 
ADAM9 in monkey kidney cells revealed a phorbol ester-induced increase in HB-EGF 
shedding (90).  This event could be precluded with ADAM9 protease domain mutants.  
However, ADAM9 deficient mice displayed no overt phenotypes and fibroblasts isolated 
from these mice showed no deficiencies in basal, or PMA-induced levels of shed HB-EGF 
(91).  ADAM12 has also been suggested as an HB-EGF sheddase since dominant negative 
ADAM12 transfected into cardiac cells inhibited GPCR-induced HB-EGF shedding (92).  
However, the ADAM12-null mice lacked any distinguishable phenotype and fibroblasts 
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derived from the null mice from one study were able to constitutively and PMA-inducibly 
shed HB-EGF in culture (93), while PMA-induced shedding was markedly decreased in 
another (94).  Sensitivity differences between the two distinct assays could account for the 
conflicting observations.  ADAM15 was implicated in TGF-α and AR shedding by knocking 
down ADAM15 expression (95,96), but shedding remained constant in fibroblasts from null 
mice (93).  A role for ADAM19 in constitutive neuregulin cleavage was insinuated from 
mouse cells overexpressing wild type and dominant negative ADAM19 mutants, which 
increased and inhibited, respectively, shedding of NRG1β (97).  Therefore while ADAM-9, -
12, -15, -19 may be capable of cleaving ErbB ligands, genetic evidence does not support 
this as a primary responsibility.   
   ADAM10 and ADAM17 share unique characteristics that may separate them from other 
family members.  As mentioned above, other ADAMs and MMPs employ the cysteine switch 
mechanism for inhibition of the catalytic activity during transport, while these ADAMs do not, 
relying on other determinants to alter the conformation of this domain (63,66).  Comparison 
of the metalloprotease sequences of ADAM10 and ADAM17 predict surface protuberances 
found in the TACE structure that may function in substrate specificity and are not found on 
any other ADAMS (58).  The primary function of these proteins appears to be as 
metalloproteases, with only minor roles as adhesion molecules since only two integrin 
interactions have been ascribed to either ADAM.  Also, among the ADAMs, only knockouts 
of ADAM10, ADAM17 and ADAM19 caused lethality of homozygous mutant offspring, 
implying a requirement for these metalloproteases that cannot be compensated for by 
redundant functions of other ADAMs (47,98,99).  ADAM10 knockout mice die due to central 
nervous system defects and insufficient development of the cardiovascular system (98).  
ADAM10 has been described as another HB-EGF sheddase (100,101), yet again embryonic 
fibroblasts from the knockout mice shed HB-EGF up to wild type levels.  PMA-stimulated 
shedding of TGF-α, AR, EPR and EPI were also unaffected by the loss of ADAM10.  
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However, there was diminished constitutive and induced shedding of BTC and EGF 
(93,102).  These levels returned to normal following overexpression of wild type, but not 
catalytically inactive ADAM10, validating ADAM10 as a key sheddase for these ligands.  
Along with its role in ErbB shedding, ADAM10 may also function as an α-secretase of 
amyloid precursor protein (APP) forming α-sAPP and opposing formation of β-sAPP, the key 
component of plaques found in Alzheimer’s disease, and prion precursor proteins (103,104).  
ADAM10 may not be the primary, or only, protease for APP, since embryonic fibroblasts 
lacking ADAM10 are still able to produce soluble APP (98).  Furthermore, ADAM10 targets 
the Notch receptor and its ligand Delta in Drosophila and ligands of the Eph tyrosine kinase 
receptors, both critical pathways in neuronal development and control of cell fate (105,106). 
   ADAM17 was first identified by its ability to cleave Tumor Necrosis Factor-α (TNF-α), 
hence its more widely known designation TNF-α Converting Enzyme (TACE), but is also the 
major EGF-like growth factor sheddase.  Mice deficient in TACE activity, due to removal of 
the exon that encodes the zinc binding domain (TACE ΔZn/ΔZn), exhibited perinatal lethality 
in a majority of pups, that could not be attributed to a lack of TNF-α, since TNF-α and TNF 
receptor null mice survived to adulthood (107,108).  TACE ΔZn/ΔZn newborns that survived 
displayed several epithelial defects that resembled the phenotypes found in both EGFR and 
TGF-α null mice, namely: open eyelids, stunted vibrissae, wavy hair and impaired 
development of the respiratory and digestive tracts (29,47).  Embryonic fibroblasts derived 
from these mice were impaired in shedding of TGF-α, HB-EGF and AR.  Shedding could be 
partially rescued by transfection of wild type TACE into the cells (47,89,109).  This data was 
further supported by in vitro peptide cleaving assays that demonstrated purified TACE could 
cleave TGF-α, AR and HB-EGF at the correct juxtamembrane site on each growth factor 
(109) and later through comparison of AR and HB-EGF null phenotypes to TACE null mice 
(33,110).  TACE has recently been reported to also cleave EPR and EPI in cell culture 
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assays. (93,111).  TACE may also be able to cleave several isoforms of the neuregulin 
family of growth factors (112).  These cumulative findings suggest that TACE is the major 
sheddase for ErbB family ligands. 
 
Regulation of ADAM-Dependent Ectodomain Shedding  
   In addition to ErbB ligands, numerous substrates for the catalytic activity of ADAMs have 
been reported, including cytokines, adhesion proteins and ligand receptors indicating the 
need for regulation in substrate selection (61,113).  Low levels of ADAM-dependent 
ectodomain shedding occurs constitutively, but can be rapidly induced by a host of 
stimulants including other growth factors (FGF, PDGF), non-physiological phorbol esters 
(PMA), calcium ionophores, the phosphatase inhibitor pervanadate and signals from other 
receptors such as G-protein coupled receptors (GPCRs), suggesting multiple pathways for 
activation of ADAM protease activity (61).  The stimulated cleavage of EGF-like ligands 
allows GPCRs to harness EGFR downstream signaling pathways and is the central step of a 
triple membrane spanning signal required for transactivation of ErbB receptors (114) (Figure 
1.3).  This has been seen with GPCR activation of EGFR-regulated pathways such as ERK 
activation and cell proliferation (115,116).  Stressing the importance of soluble growth 
factors, metalloprotease inhibitors have been shown to block transactivation (117).  MMP2 
and 9 are implicated in HB-EGF mediated EGFR transactivation in gonadotropic cells (118), 
while MMP7 in response to phenylephrine can cleave HB-EGF in rat arteries (119).  Since 
ADAMs are implicated as the major proteases responsible for ErbB ligand cleavage, it has 
been hypothesized they could play a key role in transactivation.  Accordingly, several 
ADAMs are directly implicated in transactivation of EGFR in various cell lines and with 
numerous GPCR stimulants (120).  ADAM10 shed HB-EGF and AR in gastric cancer cells 
when the GPCR agonist interleukin-8 was used to activate EGFR (121).  ADAM10-
dependent HB-EGF shedding was also detected in response to lysophosphatidic acid (LPA) 
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and bombesin stimulation of kidney and prostate cancer cell models, respectively (96,101).  
ADAM12 and ADAM15 are also implicated in EGFR transactivation.  ADAM15 mediated 
LPA-stimulated cleavage of TGF-α and AR in bladder carcinoma cells (95,96), while 
ADAM12 stimulation of cardiac myocytes, shed HB-EGF in response to phenylephrine (92).  
The evidence for TACE as a mediator of transactivation is abundant.  GPCR-induced TACE-
dependent shedding of TGF-α and HB-EGF was observed in response to angiotensin II 
(AngII) treatment of vascular smooth muscle cells, kidney cells and COS7 cells (95,122-
124), while AR was shed from squamous cell carcinoma cells in response to LPA and an 
active ingredient in marijuana, THC (114, 254).  Thus, ADAMs and in particular, TACE, are 
key regulators of EGFR transactivation.   
 
Mechanisms of Regulation 
   Despite their central role, little is known about the specificity and upstream regulation of 
ADAMs.  Cell type (or tissue) along with stimulant appear to be important determinants in 
targeting growth factors for cleavage, but this alone does not address the protease 
activation mechanism or issues of substrate selectivity.  The prodomain inhibition of ADAMs 
is one level of regulation, but with removal believed to occur prior to surface localization it is 
not believed to be the only layer for regulation of protease activity (125).  The cytoplasmic 
domain of ADAMs can be phosphorylated, interact with proteins and have recognized 
signaling motifs that may allow them to regulate inside-out signaling.  While the decisive 
regulation mechanism for TACE activity has not been determined, several reports identify 
potential regulatory mechanisms that include substrate presentation, activation by 
phosphorylation, participation in protein interactions, stimulation of translocation, a role for 
common signaling pathways and second messenger production.  With the diversity of 
substrates and abundant stimulants, a complex assortment of mechanisms may be required 
to determine substrate specificity and regulation of function. 
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 Influence of the Substrate 
   The target substrate of ADAM-directed cleavage could have a profound effect on the 
ability of metalloproteases to function.  It has been repeatedly proven that the primary 
sequence of the substrate cleavage site for TACE and ADAM10 has no bearing on 
selection.  Instead it appears to be a combination of the distance from the membrane along 
with conformation and surrounding residues that permit access of the protease active site to 
the cleavage site (89,126-129).   Proper localization and presentation of the substrate may 
also play a part in stimulated shedding.  For example, in transitional cell carcinoma (TCC) 
bladder cells a reserve of pro-HB-EGF has been found in the nucleus.  Upon stimulation 
with the known inducer of shedding, hydrogen peroxide, the ligand translocates from the 
nucleus to the plasma membrane and is then shed.  It was further shown that HB-EGF was 
deposited in lipid rafts at the cell surface possibly allowing greater access to activated 
ADAMs (see below) (130).  HB-EGF shedding can also be stimulated by the GPCR agonist 
bombesin through ADAM10 proteolysis (101).  Bombesin also enhances both the ADAM10 
and HB-EGF association with the tetraspanin CD9 (101).  This interaction, which also occurs 
with TGF-α (131), could help target ErbB ligands for shedding by positioning the substrate 
and enzyme in close proximity.  Presentation of the ADAM10-substrate ephrin-A5 plays a 
major role in regulating cleavage of this ligand.  ADAM10 constitutively associates with the 
ephrin-A5 receptor EphA3 and following membrane anchored ligand binding to the Eph 
receptor in trans (ligand and receptor on opposite cells) a new interacting site is generated 
in the ADAM10 CRD positioning the metalloprotease in such a way that cleavage is 
achieved (132).  However, an in vitro cell culture experiment revealed a requirement for 
TACE and shedding when a non-cleavable form of TGF-α did not activate EGFR (133).  
Also, no interaction between TACE and EGFR has been reported and this contradicts earlier 
evidence that TGF-α can activate EGFR in trans (48,49), raising doubts about the feasibility 
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of juxtacrine signaling by ErbB ligands.  Further evidence that the disintegrin and CRD of 
ADAMs may be responsible for substrate presentation to the metalloprotease domain 
comes from studies of the development of frogs.  Xenopus ADAM13 chimeras containing 
the ADAM10 metalloprotease domain functions the same as wild type ADAM13 in 
developing animals.  However, when the ADAM10 CRD was substituted into ADAM13, 
function was lost (134).  These examples, in conjunction with the role of the CRD in 
prodomain coordination and inhibition of ADAM10 and TACE (63), demonstrate the 
importance of the extracellular adhesion domains in regulation of the protease, likely 
through substrate selection and presentation. 
 
Role of Localization 
   ADAMs may also be regulated by spatial effects.  One potential mechanism for regulation 
of ADAMs is compartmentalization of the protease.  The ADAM10 substrate CD171 is 
constitutively cleaved in membrane-enclosed secretory vesicles, called exosomes, followed 
by extracellular release of soluble product from ovarian carcinoma cells (135).  Production of 
soluble CD171 and another cytokine, CD44, was induced in an ADAM10-dependent manner 
by an increase in intracellular calcium levels, also from exosomes (136).  TACE, however, 
stimulated by the global activator of shedding PMA in this same study, shed CD171 and 
CD44 only at the cell surface.  Conversely, the TACE substrate TNFR has also been found 
to be cleaved and released from exosome-like vesicles (137).  This implies different ADAMs 
can function in distinct compartments of the cell depending on the stimulus or substrate.   
   Micro-compartments on the cell surface comprise another region where ADAM activity is 
found.  Rafts are detergent-insoluble membrane regions rich in cholesterol and signaling 
proteins.  In cholesterol depleting experiments, which disrupt raft formation, ADAM10-
dependent amyloid precursor protein shedding was increased in neural cell lines (138), 
while ADAM10 and ADAM17 activity towards the IL-6 receptor was enhanced in COS-7 
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cells.  Shedding of the ErbB ligand NRG-β1 by ADAM19 was found to occur in rafts of 
neuronal cells (139).  TACE activity is partitioned in rafts during transport through the Golgi 
network and the mature form of TACE and its protease activity is limited to rafts in 
endothelial cells (140).  These results demonstrate the importance of rafts as negative 
regulators of ADAM protease activity by amassing ADAMs during transport through the cell 
and sequestering their activity away from potential substrates until stimulation leads to 
translocation of the substrate or ADAM.   
   Trafficking and maturation of ADAMs may also play a role in regulating activity.  The 
prodomain acts as both an inhibitor and a chaperone during passage of ADAMs through the 
secretory pathway (141).  SH3PX1 and endophilin 1 are SH3 containing proteins that utilize 
SH3 binding domains in the cytoplasmic domains of ADAM9, ADAM15 and ADAM19 to 
potentially regulate these proteins (248).  Interestingly, these proteins preferentially bind the 
pro-form of ADAM-9 and -12 over the mature forms and since endophilin is associated with 
endocytosis at synapses and SH3PX1 contains a phospholipid interacting domain, these 
may play a role in processing or transport of ADAMs prior to the removal of the prodomain.  
PKC and casein substrate in neurons (PACSINs) contain one SH3 domain and are believed 
to function in vesicle formation and transport.  PACSIN2 is an ADAM13 binding partner 
(142), while PACSIN3 interacts with ADAM-9, -10, -12, -15, and -19 (143).  Furthermore, 
PACSIN3 overexpression enhanced HB-EGF shedding in response to phorbol esters and 
the GPCR agonist AngII, while knockdown of PACSIN3 inhibited ADAM12 dependent HB-
EGF shedding (143).  This suggests that PACSIN3 is necessary for the shedding activity of 
some ADAMs, possibly through regulation of the translocation of these ADAMs.   
 
Protein Interactions 
   Along with integrins and other extracellular interactions, cytoplasmic binding partners that 
take advantage of the SH3 binding motifs may directly regulate ADAM protease activity 
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(Table 1.2).  ADAM12 also associates with the regulatory subunit of PI3K through SH3 
motifs (144).  This association is believed to be part of the regulatory mechanism of PI3K by 
mediating recruitment of this enzyme to the plasma membrane in differentiating myoblasts.  
Grb2 is a well known adaptor protein that can bind to activated EGFR to initiate Ras-MAPK 
signaling pathway.  ADAM12 and ADAM15 also interact with Grb2, but while the Grb2 
binding to ADAM15 can be mediated by phorbol ester induced phosphorylation, the effect of 
these interactions on ADAM function is unknown (145,146).   
   In contrast, the TACE cytoplasmic binding partners appear to effect protease activity.  
Eve-1 is a protein with no enzymatic domain, but numerous proline-rich and SH3 motifs that 
allow docking with signaling proteins (147).  It was shown through immunoprecipitation 
assays that ADAM-9, -10, -12 and -15 interact with Eve-1 via the ADAM SH3 binding 
domains (147).  When Eve-1 expression was knocked down, TPA stimulated HB-EGF, TGF-
α, AR and EPR shedding were all diminished.  Likewise, N-arginine dibasic convertase 
(NRDc) potentiates PMA-induced TACE protease activity towards HB-EGF (148).  NRDc is 
an active endopeptidase, but mutations to the catalytic domain had no effect on HB-EGF 
shedding, ruling out any effect of the endopeptidase function in HB-EGF shedding, or TACE 
binding (148).  Instead NRDc was shown to also interact specifically with HB-EGF, but not 
other ErbB ligands, providing another example of how substrate specific interactions may 
influence shedding (149).  Another interacting protein lacking enzymatic domains is a 
Synapse Associated Protein (SAP97) that binds TACE at the very C-terminus at a novel 
PDZ domain (150).  These two proteins also colocalize early in the secretory pathway, 
suggesting SAP97 may function in TACE maturation.  The interaction also regulated TACE 
protease activity.  Overexpressed SAP97 inhibited TACE-dependent shedding of TNF-α and 
TNFR, whereas overexpression of a SAP97 mutant incapable of binding TACE had no 
effect.  The TACE interaction and phosphatase activity of protein tyrosine phosphatase H1 
(PTPH1) negatively regulates TACE cleavage of TNF-α, although this affect has not been 
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examined on ErbB ligands (151).  While the mechanism of regulation is unknown and the 
relationship or function of these interactions has not been tested following GPCR 
stimulation, these results demonstrate that interactions can influence protease activity and 
that interaction partners may specify unique substrates for cleavage. 
 
Signaling Intermediates Implicated in Activation of ADAMs 
   Many signaling intermediates have been implicated in pathways that lead to the activation 
of ADAM metalloprotease activity.  These pathways include MAPK proteins, non-receptor 
Src family tyrosine kinases, PKC, and signaling molecules such as calcium and reactive 
oxygen species. 
   The MAPK signaling pathway is an intermediate in many signaling schemes including 
those directly downstream of GPCR signaling that can lead to ectodomain shedding.  
However, it is difficult to differentiate between MAPK signaling initiated directly by GPCRs 
versus MAPK signaling activated by EGFR.  As expected, GPCR transactivation leads to 
EGFR-dependent Ras/Raf/MEK/ERK activation (117).  TACE knockdown, but not ADAM12 
knockdown, in head and neck squamous cell carcinoma cells (SCC-9) led to loss of EGFR 
phosphorylation and downstream signaling induced by LPA and carbachol (114).  However, 
MAPK pathways may also be directly activated by GPCRs and involved in ADAM regulation.  
The stress response pathway comprising the p38 MAPK can mediate ADAM-dependent 
shedding of HB-EGF and TGF-α in a variety of cell types (152-154).  Stress-inducing 
reagents elevated p38 phosphorylation and subsequent HB-EGF shedding that also could 
be induced with constitutively active p38 mutants and blocked by dominant negative p38 
mutants (152).  Interestingly, phorbol ester and LPA induced shedding were not affected by 
p38 inhibitors indicating specific signals that utilize p38 in activating shedding (154).  For 
TGF-α, p38 functioned only in constitutive shedding as growth factor stimulation was able to 
induce production of soluble TGF-α (153).  Fan and Derynck (153) also reported a role for 
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another MAPK protein, MEK1, in inducible, but not constitutive TGF-α shedding stimulated 
by other receptor tyrosine kinases.  Only when inhibitors of both pathways were combined 
was fibroblast growth factor-induced shedding completely abolished (153).  Pervanadate 
directed ADAM10 shedding of the neural cell adhesion molecule (NCAM) through ERK1/2 
(155) and PMA stimulated shedding of the TACE substrates L1 and HB-EGF that was 
dependent on the active kinase MEK (135,156).  MEK is an upstream activator of ERK and 
could induce the Erk:TACE interaction and subsequent phosphorylation that regulates 
TACE transport to the cell surface following PMA stimulation (86).  Montero et al. (157) have 
also reported on the role of MAPK in TGF-α shedding from CHO cells.  In this report, MAPK 
inhibition using the same reagents described above only partially blocked PMA stimulated 
TGF-α shedding demonstrating a MAPK-independent pathway by phorbol esters.  Further 
supporting the idea of dual pathways, the GPCR agonist LPA requires MEK activity to 
mediate HB-EGF shedding by an unidentified ADAM in Vero-H cells, while phorbol ester-
induced HB-EGF shedding was independent of MEK signaling (158).  This is, however, the 
only example of Ras-Raf-MEK signaling mediating GPCR-induced EGF-like shedding.  
Taken together, it appears that MAPK pathways do have a role in regulation of ADAMs 
depending on the signal and cell type, but only in response to certain conditions.  This does 
not rule out alternative pathways that may also lead to shedding and leaves the exact 
situations for which MAPK pathways are applied to be determined. 
   Cytosolic nonreceptor tyrosine kinases, like Src family proteins, have been implicated in 
EGFR transactivation (159-163), though only recently has their precise role been 
scrutinized.  HB-EGF shedding following activation of andrenergic GPCRs was sensitive to 
c-Src inhibitors (115), while carbachol stimulated TGF-α shedding was dependent on Src-
like CADTK/PYK2 nonreceptor tyrosine kinase activity (164).  Src-family kinases can also 
directly interact with the SH3 domains of several ADAMs (Table 1.2).  Src interacts with 
ADAM-9, -12, -13, and-15; Abl interacts with ADAM-12, -13, and -15; Yes can bind 
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ADAM12; Lck associates with ADAM-10 and -15; Fyn, and Hck, so far, only bind to 
ADAM15.  The ADAM15 interactions with Hck and Lck were dependent on ADAM15 
cytoplasmic phosphorylation, though the kinase responsible is not known (145).  The 
ADAM12 interaction with v-Src leads to phosphorylation of ADAM12 in muscle cells, and 
although this interaction activates Src, the affect on ADAM12 function is unknown (146,165).  
Providing the most comprehensive study of Src signaling to date, Zhang et al. (166) showed 
that Src association with TACE is part of a mechanism that activates PI3K and causes 
phosphoinositol dependent kinase-1 (PDK1) to directly phosphorylate serines and 
threonines in TACE, leading to AR shedding and activation of EGFR.  Finally, the Src 
substrate Fish is a scaffolding protein that binds ADAM-12, -15, and -19 (167) and could 
mediate substrate presentation, or protease regulation, of these ADAMs through formation 
of complexes with secondary binding sites.  Thus, Src proteins can function upstream of 
ADAMs in some scenarios, though their function is not well understood on a mechanistic 
level.  
   Protein Kinase C (PKC) is another family of signaling proteins involved in ADAM regulation 
via Ser/Thr phosphorylation as a regulatory modification.  PKC can be activated by phorbol 
esters, which are general activators of shedding.  Though a non-physiologic stimulus, the 
mechanism by which PMA-activated PKC regulates ADAM activity is nevertheless of 
interest.  ADAM9 associates with PKC-δ and that this phorbol ester-induced interaction can 
regulate ADAM9 dependent HB-EGF shedding (90).  ADAM9 was phosphorylated in 
response PMA (85), but whether or not this is a direct result of PKC binding, or its affect on 
ADAM9 activity, is not known.  ADAM12 can also associate with PKC-δ and PKC-ε (92,168).  
PKC-ε regulates ADAM12 translocation from a perinuclear compartment to the cell surface 
upon stimulation with PMA (168).  This event was dependent on the cytoplasmic binding 
and kinase activity of PKC-ε, though direct phosphorylation of ADAM12 was not 
investigated.  PKC was identified upstream of EGFR transactivation by carbachol in human 
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embryonic kidney 293 cells (169) and again in hepatic C9 cells in response to AngII (170).  
PKC-δ, using specific PKC inhibitors, was later situated in between upstream calcium and 
Src signaling and downstream EGFR transactivation by phenylephrine in neurons and 293 
cells (171).  PKC isoforms are modulated by diacylglycerol (DAG), which in turn are 
regulated by DAG kinase (DGK) (172).  Thus, it was of great interest when DGK-δ knockout 
mice displayed EGFR and TACE-like open-eye phenotypes and enhanced activation of PKC 
and PKC substrates (173).  This suggests DGK can influence EGFR signaling, but whether 
this is dependent on shedding is under investigation.  Together, this evidence proves a 
necessary role for PKC, but also supports the contention that multiple signaling pathways 
can converge on ADAMs to activate shedding. 
   Second messengers are diffusible signaling molecules commonly used as intermediates 
for signal transduction utilized by GPCRs and other receptor initiated pathways.  Calcium is 
a common downstream target of G-proteins and participates in EGFR transactivation (174-
176).  Extracellular calcium uptake, which initiates signaling, can be reproduced using an 
ionophore to transport calcium across the membrane and this has been shown in several 
independent reports to specifically trigger ADAM10-dependent shedding.  This led to 
cleavage of the cell adhesion molecule CD44 by ADAM10, whereas TACE-dependent CD-
44 shedding was regulated by PKC (177).  Calcium also regulated shedding of the ADAM10 
specific substrates EGF and BTC (89,102).  TACE substrates TGF-α, AR, HB-EGF and 
EPR could also be shed by intracellular calcium increases, but independent of TACE 
activity, implicating other metalloproteases and demonstrating how various stimuli can target 
different proteases and substrates.   
   Calcium has been reported upstream of TACE-dependent HB-EGF shedding in COS7 
cells.  Using phospholipase-C activators, a calcium ionophore and dominant negative TACE, 
Mifune et al. (123) elucidated an AngII pathway that utilized phospholipase C-Ca-ROS-
TACE-HB-EGF in transactivation of EGFR.  How calcium influences TACE activity may be 
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explained through involvement of another second messenger, reactive oxygen species 
(ROS).  ROS are byproducts of oxidative phosphorylation in the mitochondria and the 
reduction of NADPH by its oxidase in the cytoplasm of most cells along with a host of other 
oxidases such as xanthine oxidase, cyclooxygenase, lipoxygenase and nitric oxide (178).  
They are known to promote a variety of cellular events through their stimulated production 
following signaling by GPCRs, cytokines and stress inducing agents.  The ROS, hydrogen 
peroxide, can stimulate the shedding of TGF-α, AR, TNFR and L-selectin by TACE 
(100,179,180).  HB-EGF shedding mediated by ADAM10, TACE and to a lesser extent 
ADAM9 (152), utilized the p38 MAPK pathway, however in rat prostate cancer cells HB-EGF 
shedding involving ROS was independent of p38 signaling (181).  ROS activation of TACE 
and ErbB ligand shedding is important in many physiologically relevant transactivation 
events, too.  Insulin growth factor-1 receptor and endothelin-1 receptors can transactivate 
EGFR through ROS-stimulated ADAM-directed shedding of HB-EGF (182,183).  
Transactivation of EGFR regulates mucin expression in airway epithelial cells relying on 
TACE shedding of TGF-α initiated by ROS production from NADPH oxidase (Nox) to 
propagate the signal (179).  In vascular smooth muscle cells, phenylephrine and angiotensin 
II induce proliferation through ROS-ADAM-HB-EGF-EGFR and have become useful models 
for cardiovascular disease (123,180).  Angiotensin II (184) and phenylephrine (180), along 
with endothelin I (185), appear to utilize Nox complex as the main source of ROS by 
activating Rac-1 (186), which is responsible for the phosphorylation and translocation of the 
cytoplasmic subunits of Nox to the membrane where they interact with and form a 
functioning complex (187).  Several reports suggest that Src kinases may play a role in Nox 
activation and ROS production following GPCR activation (171,186,188).  Zhang et al. (189) 
showed that hydrogen peroxide might directly activate TACE metalloprotease by removing a 
peptide mimic of the TACE prodomain in an in vitro peptide cleavage assay.  This 
corresponds with the ability of ROS to oxidize cysteine residues as a modification.  ROS 
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may also regulate ADAM activity through oxidation of lipid moieties, or targeting of 
cholesterol, which may alter lipid raft integrity.  Thus, calcium and ROS, or even calcium 
upregulating ROS, are positioned as key determinants in selection of substrate and 
activation of ADAMs, though exactly where and how are undetermined. 
 
   The importance of the ErbB network, and by extension ligand shedding, has been 
established through the studies concerning development and the role of disregulated 
signaling in disease progression.  Since GPCRs appear to routinely utilize EGFR to 
integrate and amplify hormone signaling, transactivation of EGFR may also play an 
important role in development of cardiovascular diseases, lung fibrosis and asthma, and 
Alzheimer’s disease.  The dependence on soluble ligand indicated by the requirement of 
metalloproteases from Prenzel et al. (117) reveals how indispensable shedding is and how 
regulation of this central process could be crucial.  ADAMs have been implicated in this 
shedding event through genetic and biochemical studies of TACE and ADAM10 knockout 
mice and in cell culture models, yet substrate specificity and enzymatic regulation are still 
not fully understood.  The evidence so far points to many different levels of regulation that 
could cooperate to control ADAM and ectodomain shedding.  Signaling molecules and 
pathways, such as calcium, ROS and MAPK, translate external ligand binding to ADAM 
activation by yet unknown mechanisms.  Other signals, such as those transmitted by PKC 
and Src-like kinases, may alter localization and protein interactions that regulate 
associations of enzyme with its substrate.  Still for all that has been discovered, 
contradictions remain and there remains much to learn.  Thus, refining and improving our 
understanding of ADAM regulation mechanisms is the current focus of this field with the 
hope that each advance in our knowledge of ADAM-dependent shedding brings us closer to 
understanding and development of novel treatments for any number of diseases. 
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Table 1.1  ADAM, Integrin Interactions 
 
ADAM Integrin Reference 
ADAM1 α9β1 77, 234 
ADAM2 α4β1, α6β1, α9β1 77, 234, 235 
ADAM3 α4β1, α6β1, α9β1 77, 234, 236 
ADAM7 α4β1, α4β7, α9β1 237 
ADAM8 α9β1 238 
ADAM9 α2β1, α3β1, α6β1, α6β4, 
α9β1, αvβ5 
82, 77, 239, 240, 241 
ADAM12 α4β1, α9β1, α3β1, α7β1, 
β1, β3 
77, 79, 81, 83, 242, 243, 
244 
ADAM15 α5β1, α9β1, αIIβ3, αvβ3 75, 76, 77, 245  
ADAM17 α5β1 80 
ADAM19 α4β1, α5β1 79 
ADAM23 αvβ3 246 
ADAM28 α4β1, α4β7, α9β1,  11, 237 
ADAM33 α4β1, α5β1, α9β1 79, 247 
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Table 1.2  Selected ADAM Protein Interactions 
 
ADAM Interacting Protein Identifying 
Technique 
Reference 
ADAM9 Enophilin-1 
Eve-1 
Fish  
MAD2β 
PACSIN3 
PKCδ 
SH3PXI 
Src 
Y2H, GST-pd 
tIP 
tIP 
Y2H, GST-PD 
Y2H 
FW, tIP 
Y2H, GST-PD 
FW 
248 
147 
167 
249 
143 
90 
248 
250 
ADAM10 Eve-1 
Lck 
MAD2 
PACSIN3 
tIP 
GST-PD 
GST-PD 
Y2H 
147 
145 
145 
143 
ADAM12 Abl 
Actinin-1 
Actinin-2 
Eve-1 
Fish 
Grb2 
MAD2β 
PACSIN3 
p85-PI3K 
PKCδ 
PKCε 
Yes 
GST-PD 
FW, GST-PD, tIP 
Y2H, GST-PD, tIP 
Y2H, tIP 
tIP 
GST-PD, eIP 
Y2H 
Y2H, GST-PD, tIP 
GST-PD, tIP 
Y2H 
eIP 
GST-PD 
146 
251 
252 
147 
167 
146 
249 
143 
144 
92 
168 
146 
ADAM15 Abl 
Endophilin-1 
Eve-1 
Fish 
Fyn 
Grb-2 
Hck 
Lck 
MAD2β 
PACSIN3 
SH3PX1 
Src 
GST-PD 
Y2H, GST-PD 
tIP 
tIP 
GST-PD 
GST-PD 
GST-PD, tIP, FW 
GST-PD, eIP, FW 
Y2H 
Y2H 
Y2H, GST-PD 
GST-PD 
145 
248 
147 
167 
145 
145 
145 
145 
249 
143 
248 
145 
ADAM17 ERK 
Eve-1 
MAD2 
NRDc 
PTPH1 
SAP97 
GST-PD, eIP 
tIP 
GST-PD 
tIP 
Y2H, GST-PD, tIP 
Y2H, GST-PD, eIP 
232 
147 
249 
148 
151 
150 
ADAM19 ArgBP1 
b-Cop 
Endophilin-1 
Fish 
PACSIN3 
Ubiquitin 
Y2H, GST-PD 
Y2H 
Y2H 
PD, GST-PD, tIP 
Y2H 
Y2H 
253 
253 
253 
167 
143 
253 
Technique key: eIP, endogenous immunoprecipitation; tIP, transfected immunoprecipitation; FW, far 
western; GST-PD, glutathione-S-transferase pulldown; PD, phage display; Y2H, yeast two-hybrid. 
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Figure 1.1  The EGF-Like Growth Factors.  Schematic of the seven EGF-like growth factors.  
Epidermal growth factor possesses an N-terminal extension consisting of eight EGF-like 
motifs (dashed lines).  All other N-terminal extensions are indicated by solid lines.  The N-
terminal cleavage sites are designated by black arrows, while the C-terminal cleavage sites 
are illustrated with grey arrows.  These polypeptide ligands begin as membrane anchored 
precursor proteins.  They all contain an approximately 50 amino acid receptor binding region 
that is folded into a three loop structure, formed by disulfide bonds between six conserved 
cysteines.  This region is found in the ectodomain of the protein, a short distance above the 
membrane. 
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Figure 1.2  ADAM Domain Sequence.  A schematic of disintegrin and metalloproteases 
(ADAMs) and their relationship to snake venom metalloproteases and matrix 
metalloproteases.  Note matrix metalloproteases may include domains such as hemopexin-
like and proline-rich regions that participate in substrate selection and protein interactions, 
C-terminal to the catalytic domain.  SP, signal peptide; Pro, prodomain; MP, 
metalloprotease; Dis, disintegrin; CRD, cysteine-rich domain; TM, transmembrane domain; 
Cyto, cytoplasmic domain. 
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Figure 1.2 
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Figure 1.3  Triple Membrane Passing Transactivation Pathway.  Paradigm for transactivation 
of EGFR following GPCR stimulation.  A GPCR agonist binds and stimulates G-protein 
signaling that eventually leads to the activation of ADAM metalloproteases, which is possibly 
dependent on the cytoplasmic domains of ADAMs.  The protease cleaves membrane 
anchored growth factors, which bind EGFR and initiate downstream signaling pathways 
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Figure 1.3 
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Chapter 2 
 
 
 
 
Purinergic GPCRs Utilize Mitochondrial ROS to Mediate TACE-Dependent TGF-α Shedding 
 
 
 
 
 
 
 
 
 
This work has been submitted to the American Society of Microbiology for publication in the 
journal Molecular and Cellular Biology.  Myers, T. J., Brennaman, L. H., Stevenson, M., 
Higashiyama, S., Russell, W. E., Lee, D. C. and Sunnarborg, S. W.  
This work was a collaborative effort.  I collected conditioned media for analysis by RIA 
following pretreatment with NAC in Table 2.1 and Figure 2.3, RT-PCR experiments for 
murine and CHO cells (Figures 2.2 and 2.4), all AP shedding assays in Figures 2.4 and 
2.5 along with measurements of ATP induced mitochondrial ROS in Figure 2.5.  All RIA 
media analysis was performed by Mary Stevenson under William E. Russell.  Detection 
of EGFR phosphorylation was performed by Susan Sunnarborg, while collection of 
conditioned media for RIA analysis in Figures 2.1, 2.2 and Table 2.1 were performed by 
Susan Sunnarborg and Leann Brennaman. 
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Abstract 
 
     EGFR transactivation by GPCRs has been shown to regulate many essential 
biological processes.  ADAM metalloprotease activity has been implicated as a key step 
in transactivation, yet the regulation mechanisms are not fully understood.  Here, we 
investigate the regulation of TGF-α shedding through the ATP-dependent activation of 
the P2Y family of GPCRs.  We report that ATP stimulates TGF-α proteolysis with 
concomitant EGFR activation and that this process requires ADAM17/TACE activity in 
both murine and CHO cells.  ATP-induced TGF-α shedding was independent of Src 
family kinases, PKC and MAPK signaling, but could be stimulated by a calcium 
ionophore.  Moreover, ATP-induced TGF-α shedding was completely inhibited by 
scavengers of reactive oxygen species (ROS) and stimulated by hydrogen peroxide, 
while stimulation with the calcium ionophore was partially inhibited by reduction of ROS 
in the cell.  We also found that the cytoplasmic NADPH oxidase complex was not 
required for ATP-induced shedding.  Instead, mitochondrial ROS production increased in 
response to ATP and mitochondrial oxidative complex activity was required to activate 
TACE-dependent shedding.  This study reveals the requirement for mitochondrial ROS 
in regulating GPCR-induced growth factor shedding. 
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Introduction 
   Epidermal growth factor receptor (EGFR) has long been recognized as a critical 
component of cellular signal transduction machinery (2).  The recent discovery of the 
essential role of EGFR in propagating signals generated by G-protein coupled receptor 
(GPCR) agonists indicates that EGFR may function as a central signal integration point 
for stimuli impacting the cell surface (59,120).  A wide variety of GPCR agonists, 
including lysophosphatidic acid (LPA), phenylephrine and carbachol, can harness EGFR 
to promote ERK activation leading to physiological and patho-physiological processes 
(95,101,114,180).  Until recently, GPCR crosstalk was thought to consist of entirely 
intracellular signaling pathways that led to EGFR phosphorylation, independent of ligand 
binding and dimerization.  However, elucidation of a rapid, metalloprotease-dependent 
growth factor cleavage step leading to EGFR activation (117) revealed the importance of 
regulated proteolysis in GPCR-EGFR transactivation.   
   The seven known members of the EGF family of growth factors, amphiregulin (AR), 
betacellulin, EGF, epigen, epiregulin, heparin-binding EGF (HB-EGF), and transforming 
growth factor alpha (TGF-α), are all initially synthesized as type I transmembrane 
precursors, containing the growth factor moiety in the ectodomain (19).  Several studies 
have demonstrated the biological activity of the non-cleavable, membrane anchored 
precursor molecules (48,49), but the metalloprotease dependence of transactivation, the 
loss of EGFR signaling in cells inhibited with metalloprotease inhibitors (133,190), and 
the convergence of phenotypes of growth factor, growth factor receptor and protease 
knockout models indicate that proteolytic cleavage of the growth factors is an important 
and regulatable step in most contexts (33, 34, 47, 110).   
   A variety of in vitro and in vivo evidence points to the ADAM family member Tumor 
Necrosis Factor Alpha Converting Enzyme (TACE/ADAM17) as the critical convertase 
for TGF-α, AR and HB-EGF.  ADAMs (A Disintegrin And Metalloprotease), along with 
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matrix metalloproteases, belong to the metzincin family of zinc-dependent proteases.  
When mice lacking active TACE were compared to TGF-α, AR and HB-EGF knockouts, 
they were found to share epidermal defects with homozygous TGF-α null mice (47), loss 
of mammary gland branching as in mice lacking AR (110), and heart and lung defects 
with HB-EGF -/- animals (33,34).  Fibroblasts derived from the TACE-deficient mice 
were impaired in shedding of TGF-α, HB-EGF and AR, but shedding could be partially 
rescued by transfection of wild type TACE into the cells (93,109).  In cell culture, 
knockdown of TACE expression can also have an inhibitory effect on growth factor-
dependent transactivation by LPA and angiotensin II stimulation (96,123).  The 
overlapping phenotypes of mice lacking these growth factors and those lacking 
TACE/ADAM17, along with the in vitro results, support a critical role for the soluble forms 
of the growth factors and highlight the importance of their proteolysis as a regulatory 
step.   
   Despite its presence at a critical signaling juncture, the regulation of ADAM 
metalloprotease activity is still not fully understood.  ADAMs are type I transmembrane 
proteins that possess an archetypal organization, including the metalloprotease and 
disintegrin domains along with a cytoplasmic domain often rich in SH3 binding sites that 
could potentially regulate ADAM inside-out signaling (59,61).  Recently, several signaling 
components have been implicated in GPCR-initiated TACE activation.  Src-like non 
receptor tyrosine kinases are accepted as intermediates in EGFR transactivation and 
have been found in association with several ADAMs leading to phosphorylation of ADAM 
cytoplasmic domains (61,115,166,191).  Elevation of intracellular calcium was also found 
to stimulate the release of ErbB ligands in an ADAM-dependent manner (89,102,123), 
while PKC is suspected to play a role in ADAM activation because of the ability of PMA 
to trigger PKC signaling and stimulated ectodomain shedding.  MAPK proteins have also 
been implicated both prior and subsequent to EGFR activation (114,117,152,158).  
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Lastly, reactive oxygen species (ROS) can function as a second messenger in response 
to G-protein signaling (189,192).  ROS has been shown to be necessary for Angiotensin 
II and endothelin-1 mediated TACE activation and HB-EGF shedding, possibly through 
direct modification of a cysteine that coordinates the binding of the inhibitory prodomain 
(123,185,189).  The wide variety of possible regulatory mechanisms suggests substrate- 
or cell type-specific pathways dependent on the stimulant, or intended signal effect.   
   In this study we characterize a P2Y-initiated pathway that, in response to ATP, 
stimulates TACE-dependent TGF-α proteolysis and EGFR phosphorylation, independent 
of Src, PKC and MAPK signaling.  We report for the first time the requirement for 
mitochondrially-derived ROS, whose production is stimulated by ATP, for regulation of 
GPCR-stimulated growth factor shedding.  Collectively these results offer a model that 
can be utilized to further our understanding of the activation mechanisms of TACE. 
 
Materials and Methods 
Materials – RC-20 antibody was purchased from Transduction Laboratories and MF9 
anti-human TGF-α came form Lab Vision Corporation.  The rabbit anti-EGFR, antibody, 
ERCT, was a generous gift from H.Shelton Earp (193).  Horseradish peroxidase-
conjugated secondary antibodies were from Roche Molecular Biochemicals.  Adenosine 
Triphosphate was purchased from Amersham.  N-Acetyl-L-Cysteine, rotenone and 
myxothiazol were from Sigma and all other chemicals were from Calbiochem. 
 
Cell Lines, Transfections, and Stable Clones – EC-4 (Tace+/+) and EC-2 (TaceΔZn/ΔZn) 
fibroblasts (88) and their derivatives were maintained in Dulbecco’s modified Eagle’s 
medium/F-12, 1% FBS with antibiotic.  Wild type and M2 CHO cells and their derivatives 
were maintained in Dulbecco’s modified Eagle’s medium, 10% FBS, 1x non-essential 
amino acids and antibiotic.  Transfections were performed using lipofectAMINE 
44
(Invitrogen).  The human EGFR cDNA (194) was subcloned into modified pCEP4 
(Invitrogen) and stably expressed in all cell lines following selection with 800 μg/mL 
hygromycin B (Roche).  Alkaline phosphatase-tagged TGF-α (35) was kindly sent by Dr. 
Carl Blobel.  Stable expression of AP-TGF-α in wild type CHO cells was achieved by 
selecting clones in 500 μg/mL of G418 (Sigma).  For stable expression in M2 cells that 
had already been subjected to G418 selection, AP-TGF-α was subcloned into pcDNA 
3.1 Hygro vector (Invitrogen) using a PCR-generated fragment (Hind III-capped forward 
PCR primer 5’-AAGCTTGTTCTAGCGGCACCGC-3’; Kpn I capped reverse PCR primer 
5’-GGTACCCGTTCTTACAGCAAAAGGC-3’) and the TOPO cloning kit (Invitrogen).  
Stable clones were selected in 800 μg/mL hygromycin B. 
   
Harvesting, Immunoprecipitation and Western Blot Analysis – Confluent cells were 
washed twice in serum free medium (SFM) and then starved for 4 hours at 37 0C in 
SFM.  Following a 5 minute stimulation, conditioned media was collected and cells 
washed in phosphate buffered saline and lysed in 1% Triton X-100 50 mM Tris, pH 7.4, 
150 mM NaCl with 10 μg/mL leupeptin, 20 μg/mL aprotinin, 1 mM phenylmethylsulfonyl 
fluride, 2 μM sodium orthovanadate, 10 mM sodium fluoride and 5 mM sodium 
molybdate.  Protein concentration was determined with a BCA assay kit (Pierce).  For 
some experiments media was concentrated using Sep-Pak C-18 reverse phase 
cartridges (Waters) and TGF-α amounts in both lysates and media measured with a 
specific radioimmunoassay (RIA) (196).  For immunoprecipitations, equal amounts of 
protein were incubated for 30 minutes in primary antibody at 4 0C followed by rProtein 
Agarose G (Invitrogen) at 4 0C for 1 hour.  Beads were washed three times in 20 mM 
Tris, pH 7.5, 0.1 M NaCl, 0.1 mM EDTA, 0.1% Nonidet P-40 and protein was eluted in 
Laemmilli’s sample buffer.  Proteins were separated by SDS-PAGE and transferred to 
Immobilon polyvinylidene difluoride (Millipore).  Membranes were blocked in Tris-
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buffered saline, 0.1% Tween 20, 5% nonfat milk or 3% BSA for pTyr immunoblots.  
Bands were visualized using Pierce SuperSignal West Pico chemiluminescent system 
for autoradiography. 
 
Expression of P2Y Receptors by RT-PCR – RNA was extracted from wild type EC-4 or 
CHO cells grown in 10-cm dishes using RNeasy Mini Kit (Qiagen).  Total RNA was used 
to prepare cDNA with MMTV Reverse Transcriptase (Invitrogen).  PCR amplification 
used primers for mouse P2Y2 or P2Y4 corresponding to analogour regions to yield the 
same size products.  Primers for P2Y2, 5’-ACGGTGCTCTGCAAGCTGGTGC -3’; 5’-
GTAGAGGGTGCGCGTGACGTGG-3’; P2Y4, 5’-TACTACTATGCTGCCAGAAACCAC-
3’; 5’-AGCAAAGACAGTCAGCACCACAGC-‘3.  
 
Alkaline Phosphatase Assay – Cells were plated in 24-well dishes at a density of 2.5 x 
105 for 18 hours.  Cells were washed twice in SFM and starved in fresh SFM for 4 hours 
at 37 0C.  Vehichle (DMSO) or inhibitors were added directly to cells for 30 minutes: NAC 
5 mM, apocynin 1 mM, rotenone 25 μM, myxothiazol 1 μM.  After inhibition, media was 
changed to fresh SFM containing inhibitor and stimulant for 5 minutes.  Media was then 
collected, centrifuged for 30 minutes, 14,000 xg at 4 0C.  Media aliquots were mixed with 
an equal volume of 2x AP buffer (0.1 M glycine, 1 mM MgCl2 , 1 mM ZnCl2, 5.4 mM p-
nitrophenylphosphate) and allowed to develop at room temperature.  Absorbance at 405 
nm was measured to quantify alkaline phosphatase activity.   
 
Measurement of Mitochondrial ROS – Cells were plated in 24-well dishes at a density of 
2.5 x 105 for 18 hours.  Cells were washed twice in SFM and starved in fresh SFM for 4 
hours at 37 0C.  Cells were loaded with 250 nM reduced MitoTracker Red (MTR) 
(Molecular Probes) for 15 minutes at 37 0C away from direct light.  Media was aspirated 
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and cells washed twice in phenol free serum free media supplemented with 2 mM L-
glutamine and left in washing media.  Cells were then stimulated for 5 minutes and 
excited at 544 nm and emission detected at 612 nm. 
 
Statistical Analysis – Statistical analysis was performed with assistance from the UNC 
Lineberger Comprehensive Cancer Center’s Biostatistics Shared Resources Group 
using the Wilcoxon rank sum test for pairwise group comparisons. 
    
 
 
Results 
   In order to study the regulation of proteolytic growth factor cleavage induced by GPCR 
stimulation, we chose TACE/ADAM17 cleavage of proTGF-α as a model system.  
Stimulation of EC-4 transformed fibroblasts stably expressing EGFR with the purinergic 
receptor agonist ATP led to the phosphorylation of receptor, as did treatment with 
exogenous EGF (Figure 2.1A).  Therefore, these cells possess the endogenous 
components to accomplish GPCR-induced EGFR transactivation.  
   Since EC-4 cells constitutively release low levels of TGF-α (109), we asked if ATP 
stimulation would lead to rapid release of soluble TGF-α.  ATP stimulates the murine 
purinergic P2Y2 and P2Y4 receptors with an EC50 of 100 μM (195).  Using a highly 
specific TGF-α radioimmunoassay (RIA) (196), we detected a greater than 2-fold 
increase in endogenous TGF-α shedding 5 minutes after addition of 100μM ATP (Figure 
2.1B).  The effect of ATP was not dependent on hydrolysis, as indicated by comparable 
results with the non-cleavable ATP analog, ATPγS and was comparable to shedding 
induced by the known EGFR transactivator, thrombin.  These results indicate that GPCR 
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stimulation via purinergic receptors leads to rapid release of soluble TGF-α and EGFR 
transactivation. 
   The paradigm for GPCR-induced EGFR transactivation requires a metalloprotease-
dependent growth factor cleavage step (117).  We verified the dependence on 
metalloprotease activity in this model system by treating cells with the metalloprotease 
inhibitor TAPI-2.  In the presence of inhibitor, ATP transactivation of EGFR was 
abolished, while EGF was still able to activate the receptor (Figure 2.2A).  Therefore, 
purinergic stimulation of EGFR requires metalloprotease activity.   
   In astrocytoma cells, ATP stimulated the release of amyloid precursor protein through 
P2Y2 receptors by activating both ADAM10 and TACE (197).  In our system, ATP 
stimulated TGF-α release, and as proTGF-α does not appear to be a substrate for 
ADAM10 (89,93), we hypothesized that TACE was responsible for the ATP-induced 
TGF-α release and EGFR transactivation that we have observed.  To test this 
hypothesis, we used TACE-deficient EC-2  fibroblasts (88) stably expressing EGFR.  
While EGF activated its receptor in wild-type and TACE-deficient cells, ATP was unable 
to stimulate phosphorylation of EGFR in the EC-2 cells compared to the wild type EC-4 
cells (Figure 2.2B).  Similar to our previous observations for constitutive shedding (109), 
induction of TGF-α release by treatment with 100 μM ATP was abolished in the absence 
of TACE (Figure 2.2C).  To ensure that the lack of TGF-α shedding in EC-2 cells was not 
attributable to a defect in coupling of purinergic receptors to downstream signaling, we 
monitored inositol phosphate metabolism following ATP stimulation.  EC-2 and EC-4 
cells incorporated comparable levels of 3H-inositol in response to 100 μM ATP and UTP 
(data not shown).  Thus, TACE is the crucial protease responsible for ATP-induced TGF-
α shedding in mouse fibroblasts. 
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   We also wished to determine the purinergic receptor subtype responsible for this 
shedding event.  ATP and UTP stimulated the same level of 3H -inositol incorporation 
over a range of concentrations (data not shown), a response indicative of mouse P2Y2 or 
P2Y4 receptors.  Semi-quantitative reverse transcriptase-PCR on RNA from EC mouse 
fibroblasts revealed expression of both receptor subtypes (Figure 2.2D), with higher 
levels of P2Y2 present.  Therefore, both receptors may contribute to the ATP response in 
our cell model. 
   In order to elucidate the regulatory steps of TACE-dependent shedding, we used 
chemical inhibitors to ask which pathways contributed to the release of TGF-α following 
ATP stimulation in EC-4 cells.  Pathways involving the protein kinase C family, calcium, 
and src-family non-receptor tyrosine kinases have been implicated in shedding of a 
number of EGF family members, including GPCR-induced shedding 
(89,90,102,115,164,177).  As shown in Table 2.1, reagents that target these pathways, 
including the broad spectrum PKC inhibitor bisindolylmaleimide (BIM-1), intracellular 
calcium chelator BAPTA-AM, as well as the Src family inhibitor PP2, showed no 
significant inhibition of ATP-stimulated TGF-α shedding. MAPK pathways have also 
been associated with growth factor shedding following stress or other stimuli 
(152,153,156,158,188).  However, we observed no inhibition of TGF-α release when 
ERK activity was blocked, or with either of two inhibitors of p38 MAPK signaling. This 
indicates use of an alternative route for purinergic signaling.  
   Studies of ADAM regulation, and specifically TACE, have recently focused on the 
ability of reactive oxygen species (ROS) to act as a signaling intermediate.  In vitro 
experiments have shown that hydrogen peroxide can lead to TACE activation and 
shedding of both HB-EGF and TGF-α (179,180,198).  ROS have also been found to act 
downstream of the angiotensin II receptor and P2Y purinergic receptors (123,199,200).  
We therefore hypothesized that ROS may also play a role in ATP-induced TGF-α 
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shedding.  To test this prediction, we treated mouse fibroblasts with the ROS scavenger 
N-Acetyl-L-Cysteine (NAC).  Shedding of TGF-α was dramatically reduced in the 
presence of NAC, pointing to a significant role for ROS in the regulation of TGF-α 
shedding (Table 2.1, Figure 2.3).   
   Further investigation of the source and role of ROS in the activation of TGF-α shedding 
required an assay system with high-throughput capabilities.  Alkaline phosphatase-
tagged EGF-like growth factors are an established method of monitoring the growth 
factor cleavage by quantifying alkaline phosphatase activity in conditioned media 
(35,89,93,147,152,156).  To facilitate transfection and culturing, we shifted our cell 
model to Chinese Hamster Ovary cells (CHO), which have been used previously to 
study the regulation of growth factor shedding (156,201).  While lacking endogenous 
EGF- family growth factors, they express TACE (201,202), and have been reported to 
respond to purinergic stimulation (203).  Reverse transcriptase-PCR of CHO RNA 
revealed strong expression of P2Y2, although P2Y4 was undetectable even with elevated 
cycle numbers (Figure 2.4A).  Thus, CHO cells should provide a suitable model for 
further study of GPCR-induced TGF-α shedding. 
   To test the cells and assay system we prepared wild type CHO clones that stably 
express alkaline phosphatase-tagged TGF-α (AP-TGF-α) or empty vector (35).  We next 
determined the effect of ATP on AP-TGF-α shedding.  As in mouse cells, a 5 minute 
stimulation with 100 μM ATP caused a significant increase of alkaline phosphatase 
activity in the media compared to mock stimulation (Figure 2.4B).  Metalloprotease-
dependence was verified for ATP-induced shedding by pre-treatment of the cells with 
TAPI-2.  When these cells were stimulated with water or ATP, shedding was almost 
completely abrogated (Figure 2.4B).  We next confirmed that TACE was responsible for 
AP-TGF-α shedding in CHO cells by using M2 CHO cells that carry mutations in each 
TACE allele that prohibits TACE activity (201,202).  Following ATP treatment, alkaline 
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phosphatase activity was negligible in M2-APT cells stably expressing AP-TGF-α, 
compared to wild type cells (Figure 2.4D).  These results confirm the presence of a 
P2Y2-TACE-TGF-α pathway in CHO cells.    
   We then tested the requirement for ROS signaling in the CHO cell model.  Hydrogen 
peroxide stimulated a greater than 2-fold increase in shedding over basal levels (Figure 
2.4B).  This ROS-induced increase in shedding was also dependent on metalloprotease 
activity since the inhibitor TAPI-2 prevented shedding (Figure 2.4B).  When the cells 
were pre-incubated with the scavenger NAC, ATP-induced shedding was completely lost 
as seen in the EC-4 cells (Figure 2.4C).  Thus, ROS regulation of TGF-α shedding 
appears to be a conserved pathway of P2Y receptor activation.   
   Calcium is a common signaling molecule utilized by GPCRs, especially P2Y receptors.  
Calcium has also been demonstrated to play a role in other shedding and transactivation 
studies.  We therefore tested for calcium in our pathway using a calcium ionophore, 
A23187, which mimics extracellular calcium influx by coupling to and transporting 
extracellular calcium across the membrane.  Stimulation with the calcium ionophore 
A23187 led to a significant increase in shedding over control levels (Figure 2.4E).  
A23187-induced shedding was mainly dependent on TACE activity, as shedding was 
markedly reduced in the TACE deficient M2-APT CHO cells (Figure 2.4D).  A23187-
stimulated shedding was also partially inhibited by the ROS scavenger, NAC, in wild 
type CHO-APT cells (Figure 2.4E).  These data suggest that extracellular calcium influx 
can function upstream of ROS to activate TACE-dependent shedding, but can also 
stimulate a lesser ROS and TACE independent shedding pathway.  
   Several sources of ROS exist within non-phagocytic cells, including the cytoplasmically 
bound NADPH oxidase, the mitochondrial electron transport chain, nitric oxide and 
several other oxidases (178).  In most non-phagocytic cells the NADPH oxidase 
produces the majority of cytoplasmic superoxide, which is then rapidly dismutated into 
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hydrogen peroxide (187).  To test whether the ROS required for TGF-α shedding is 
dependent on NADPH oxidase activity, we treated CHO-APT cells with apocynin, which 
blocks formation of the complete NADPH oxidase complex, thus blocking ROS 
production by this complex.  CHO cells pre-incubated with 1 mM apocynin and then 
stimulated with water, or ATP, showed no signs of inhibition (Figure 2.5A).  Comparable 
results were obtained using a range of concentrations as low as 30 μM (data not shown).  
Because several reports present evidence of a role for the NADPH oxidase in GPCR 
transactivation of EGFR (100,179,180,183,204), we also tested apocynin on 
endogenous TGF-α shedding from EC-4 mouse fibroblasts (data not shown). In 
fibroblasts as well, apocynin had no effect on ATP-stimulated TGF-α shedding, 
indicating an NADPH-oxidase independent mechanism of ROS production.  
   The electron transport chain of the mitochondrion is another major source of cellular 
ROS in cells.  To determine if the mitochondrially-derived ROS contributes to the 
regulation of TGF-α shedding, we examined two independent inhibitors of the electron 
transport chain: rotenone, which inhibits transfer of electrons from iron-sulfer centers to 
ubiquinone in Complex I, and myxothiazol, which inhibits transfer of electrons between 
cytochrome b and cytochrome c1 in Complex III.  Treatment with myxothiazol had no 
effect on basal shedding, but partially inhibited ATP-induced shedding.  A consistent 
30% decrease was measured compared to ATP alone (Figure 2.5B).  Likewise, 
rotenone, did not affect basal shedding, but it inhibited ATP-stimulated of TGF-α 
shedding by more than 65% (Figure 2.5C).  Individually these inhibitors were unable to 
inhibit shedding to the same extent as the scavenger NAC.  However, when used in 
tandem, rotenone and myxothiazol reduced shedding as efficiently as NAC (Figure 
2.5D).  These results strongly suggest that ROS produced in combination from 
mitochondrial Complex I and Complex III are an essential component of the signaling 
pathway for GPCR-induced TGF-α shedding.   
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   To determine whether ATP signaling generated increased levels of mitochondrial ROS 
we directly measured ROS using the CM-H2XRos MitoTracker Red.  This fluorescent 
dye is specifically sequestered in mitochondria and remains non-fluorescent until 
oxidized.  Cells stimulated with ATP displayed a significant, rapid increase in fluorescent 
intensity over control cells, as measured by a fluorescent platereader (Figure 2.5E).  
This increase in ROS-dependent fluorescence was inhibited by pretreatment with the 
combination of mitochondrial inhibitors rotenone and myxothiazol.  Taken together, 
these results indicate that ATP-induced signaling pathways can induce production of 
ROS from mitochondria oxidative complexes, which is an essential step in regulating 
TGF-α shedding. 
 
 
 
Discussion  
   Transactivation of EGFR via GPCR signaling has emerged as an important event for 
signal integration and amplification in many biologically essential processes, and 
typically requires a metalloprotease-mediated growth factor cleavage event (59,120).  
This study examines a transactivation pathway from the P2Y family of GPCRs that 
utilizes ADAM17/TACE metalloprotease activity to cleave TGF-α, followed by activation 
of EGFR.  Our goal was to further elucidate the signaling events leading to TACE-
mediated growth factor cleavage following stimulation with GPCR agonists.  We report 
here the first observation of mitochondrially produced ROS as a critical step in regulated 
growth factor proteolysis. 
   Extracellular nucleotides, such as ATP, are released from many cell types in response 
to stress, mechanical or biochemical stimulation (205) and can function as a paracrine 
signal for the P2Y family of purinergic receptors.  In this study we identified a P2Y-
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dependent pathway leading to TGF-α shedding and transactivation of EGFR.  More 
prominent expression of P2Y2 in mouse cells along with the lack of detectable P2Y4 
expression in CHO cells suggests a favored role for the P2Y2 subtype in this 
transactivation pathway.  P2Y2 receptors have been previously linked to EGFR 
transactivation in PC12 cells and rat fibroblasts (206,207), consistent with the ability of 
P2Y2 receptors to stimulate proliferation of epidermal keratinocytes (208) and smooth 
muscle cells (209).  P2Y2 receptors are also important for regulating ion channel function 
in epithelial cells (205).  Activation of P2Y2 can promote mucin release in airway cells, an 
event that has also been tied to TACE-dependent TGF-α shedding and EGFR 
transactivation (210,211).  Thus, elucidation of the mechanisms responsible for 
regulating EGFR transactivation pathways could have important physiological and 
therapeutic implications.  
   A recent study showed that ATP stimulation through P2Y2 receptors led to both 
ADAM10 and TACE metalloprotease activity towards amyloid precursor protein in 
astrocytoma cells (197).  Here, we show that ATP stimulated TACE-dependent TGF-α 
shedding in mouse fibroblasts, consistent with previous evidence for TACE as the major 
constitutive and PMA-stimulated TGF-α sheddase (47,89,93,109,128). A variety of 
studies have implicated roles for other ADAM proteases in TGF-α processing under 
specific conditions (89,96,201,212); however, the lack of TGF-α release and of EGFR 
transactivation in TACE-deficient cells indicates that TACE is the predominant TGF-α 
sheddase in this transactivation model as well. 
   In this study, we undertook a further examination of the signaling pathways leading to 
TACE activity.  Reactive oxygen species (ROS) have recently gained attention as 
second messengers in GPCR signaling pathways (213).  P2Y family receptors have 
been specifically linked to ROS production in eosinophils and prostate tumor cells 
(200,214).  Here we use the ROS scavenger N-acetyl-cysteine to establish a critical role 
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for ROS in P2Y receptor-dependent TGF-α shedding.  Other studies have implicated 
ROS in EGFR transactivation initiated via other GPCRs (180,183,215).  These 
observations are also consistent with reports that exogenous hydrogen peroxide 
stimulated the shedding of TGF-α and other EGF family members such as HB-EGF, 
amphiregulin, and betacellulin (100,152,179,181,183).   
   The cytoplasmic NADPH oxidase (Nox) complex, which assembles at the plasma 
membrane following cell stimulation, has been implicated as the main source of ROS in 
EGFR transactivation pathways stimulated by angiotensin II, phenylephrine, endothelin-
1 and tobacco smoke (100,180,183,204).  We investigated the involvement of the Nox 
complex in our system by using the Nox inhibitor apocynin, which directly blocks 
formation of the Nox complex.  We observed that at apocynin concentrations ranging 
from 30 μM up to 1 mM, ATP-induced TGF-α shedding was unaffected, ruling out the 
NADPH oxidase complex in this pathway.     
   To further examine the source of ROS for regulation of P2Y dependent TGF-α 
shedding, we used specific inhibitors of Complex I and Complex III of the mitochondrial 
electron transport chain to gauge the contributions of mitochondrial ROS.  The inhibitors 
myxothiazol and rotenone partially decreased shedding when used individually, but 
when used together inhibited fully, as did the general ROS scavenger NAC, indicating 
that the functional ROS generation in this pathway can be entirely attributed to 
mitochondrial sources.  Mitochondrial ROS have been implicated in aging and cell fate, 
cell responses to hypoxia and many aspects of cardiovascular remodeling and disease 
(216), as well as in hydrogen peroxide-induced EGFR activation (217) and as a 
downstream signal of EGFR (218-220).  Here, we present evidence here for 
mitochondrial ROS as a signaling intermediate for regulation of P2Y-induced, TACE-
dependent growth factor shedding.  This novel observation of mitochondrial ROS in 
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regulating shedding reveals another possible mechanism that cells may use to generate 
specificity.   
   ROS-induced TACE shedding may also involve other signaling molecules that have 
been previously implicated in EGFR transactivation.  Increases in intracellular calcium 
concentrations is a well-characterized result of GPCR activation (224) and has been 
shown to stimulate ROS production (123,199,200,204,223).  In our system, a calcium 
chelator had no effect on media TGF-α levels following ATP stimulation, indicating that 
an increase in calcium may not be a requirement for shedding, though it has been 
implicated in other P2Y2-dependent events (199).  However, a calcium ionophore did 
stimulate shedding that was largely dependent on TACE activity and was partially 
inhibited by the ROS scavenger NAC.  Since the ionophore A23187 has been shown in 
CHO BQ1 cells to induce higher levels of extracellular calcium influx than with the 
physiological ATP event (255) it may be that ionophore-induced calcium levels led to 
mitochondrial ROS production in our system.  This is consistent with reports 
demonstrating ATP, AngII and lysophosphatidylcholine stimulation of extracellular 
calcium influx and subsequent increases in ROS (123,199,200,204,223), though more 
work will be required to establish a role for calcium as a physiological, intermediate in 
ATP-induced mitochondrial ROS production.  The Ca2+-ionophore-induced residual 
shedding seen in M2 and NAC-treated wild type CHO cells may indicate a ROS- and 
TACE- independent shedding event, like that shown in mouse cells lacking functional 
TACE (89).  Taken together, these observations hint at the complexity of regulating 
specific downstream circuits following receptor stimulation.  
   PKC has been widely implicated in regulation of ectodomain shedding based on the 
well-established ability of phorbol esters to stimulate TACE-dependent TGF-α shedding 
(89,93,155).  A previous report implicated the PKC-δ isoform in regulating stimulated 
shedding of HB-EGF (90).  Inhibition of PKC with bisindolylmaleimide-1 (BIM-1, 
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GF190203X) did not affect ATP-stimulated TGF-α release in our system.  PKC has also 
been positioned upstream of Nox-dependent ROS production following PMA, 
lysophosphatidylcholine and ATP, but not angiotensin II stimulation (179,198,199,222).  
However, it may be that this pathway does not function in regulating the shedding 
response to GPCR stimulation.       
   Src family kinases have also been implicated in several GPCR-mediated 
transactivation cascades upstream of growth factor shedding, including the direct 
association of Src with TACE, that led to TACE phosphorylation and increased shedding 
of AR (166).  Other examples of P2Y2 transactivation of EGFR have demonstrated a role 
for Src including direct association with P2Y2 receptors via SH3 motifs (225).  There is 
also evidence suggesting ROS may modulate Src function in transactivation schemes 
(188,204).  In contrast, Camden et al. (197) demonstrated Src-independent activation of 
TACE and ADAM10 following ATP stimulation.  We show here that activation of TGF-α 
shedding is independent of the Src family members Src, Fyn, Hck and Lck.  This further 
underscores the selective use of available regulatory pathways for particular 
physiological events.  
   In summary, we present evidence for the first time of regulation of ATP-stimulated, 
TACE-dependent shedding of TGF-α regulated by mitochondrially derived ROS.  The 
discovery of a second source of ROS for the activation of TACE-dependent shedding 
reveals the necessary complexity of signaling that could define specificity in EGFR 
transactivation.   
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Table I   
ATP-Stimulated TGF-α Shedding Uniquely Requires ROS 
 
 
 
Inhibitor         Target               TGF-α Shedding 
PP2 Lck, fyn, hck + 
BIM-I PKC + 
BAPTA Ca2+ Chelator + 
SB202190 p38 + 
SB203580 p38 + 
U0126 MEK + 
N-Acetyl-Cysteine ROS -- 
 
       
Four replicates of EC-4 cells were pretreated for 30 minutes with the following concentration 
of inhibitors: 10 μM PP2; 20 nM BIM-I; 10 μM BAPTA; 10 μM SB202190; 10 μM SB203580; 
5 μM U0126; 5mM NAC; or vehicle (DMSO).  Following five minute stimulation with 100 μM 
ATP, conditioned media was collected and analyzed for TGF-α using a radio-immunoassay 
(196).  TGF-α levels were compared to mock inhibited samples treated with ATP.  Results 
are the average of a minimum of two experiments with at least three replicates.   
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Figure 2.1  GPCR stimulation induces EGFR transactivation and TGF-α shedding.  (A) EC-
4 EGFR cells were serum starved for 4 hours and treated with vehicle, 100 ng/mL EGF or 
100 μM ATP for 5 minutes.  EGFR was immunoprecipitated from cell lysates and 
immunoblotted with anti-phosphotyrosine antibodies.  Representative results from three 
separate experiments are shown.  (B) EC-4 cells were serum starved for 4 hours, then 
stimulated for 5 minutes with vehicle, 100 μM ATP, 100 μM ATPγS or 2 Units/mL mouse 
thrombin (Thr).  Media and lysates were harvested and concentrated as described in 
Materials and Methods, and analyzed for TGF-α content by specific RIA.  Data is presented 
as picograms of TGF-α in conditioned media per milligram of total lysate from three separate 
experiments with at least three replicates.  *, p < 0.02 as compared to the control. 
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Figure 2.2  ADAM17/TACE is required for P2Y GPCR-stimulated TGF-α shedding and 
EGFR transactivation.  EC-4 EGFR cells were serum starved for 4 hours and pretreated with 
vehicle, or 50 μM TAPI-2 for 15 minutes where indicated.  Cells were then stimulated with 
vehicle, 100 ng/mL EGF, or 100 μM ATP for 5 minutes.  EGFR was immunoprecipitated 
from cell lysates and immunoblotted with anti-phosphotyrosine antibodies.  Representative 
results of three separate experiments are shown.  (B) EC-4 EGFR or EC-2 (TaceΔZn/ΔZn) 
EGFR cells were serum starved for 4 hours then treated with vehicle, 100 ng/mL EGF, or 
100 μM ATP for 5 minutes.  EGFR was immunoprecipitated from cell lysates and 
immunoblotted with anti-phosphotyrosine antibodies.  Representative results of three 
separate experiments are shown.  (C) EC-4 and EC-2 cells were serum starved for 4 hours 
then stimulated for 5 minutes with vehicle, or 100 μM ATP.  Media and lysates were 
harvested and concentrated as described in Materials and Methods, and analyzed for TGF-
α content by specific RIA.  Data is presented as picograms of TGF-α in conditioned media 
per milligram of total lysate from three separate experiments with at least three replicates.  *, 
p < 0.05 as compared to the control. (D) Total RNA from EC-4 cells was subjected to first 
strand cDNA synthesis with, or without, reverse transcriptase and amplified for 28 cycles to 
detect the expression of P2Y2 and P2Y4 receptors. 
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Figure 2.3  ROS mediate ATP-induced TGF-α shedding.  EC-4 cells were serum starved for 
4 hours then pretreated with vehicle, or 5 mM NAC for 30 minutes.  Cells were then 
stimulated for 5 minutes with vehicle, or 100 μM ATP.  Media and lysates were harvested 
and concentrated as described in Materials and Methods, and analyzed for TGF-α content 
by specific RIA.  Data is presented as picograms of TGF-α in conditioned media per 
milligram of total lysate from three separate experiments with at least three replicates.  *, p < 
0.001 as compared to the stimulated control. 
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Figure 2.4  CHO cells demonstrate P2Y2-TACE-TGF-α shedding.  (A) Total RNA from CHO 
cells was subjected to first strand cDNA synthesis with, or without, reverse transcriptase and 
amplified over 28 cycles to detect the expression of P2Y2 and P2Y4 receptors.  Comparable 
sized products are expected as seen in Figure 2.2D.  (B) CHO-APT cells were serum 
starved for 4 hours and pretreated with vehicle, or 25 μM TAPI-2 for 30 minutes where 
indicated.  Cells were then stimulated for 5 minutes with vehicle, 100 μM ATP, or 30 μM 
hydrogen peroxide (HP).  Media was collected and analyzed for alkaline phosphatase 
activity.  Results are an average of three separate experiments with at least three replicates.  
Alkaline phosphatase activity is presented relative to the unstimulated control.  *, p < 0.001 
as compared to control.  (C) CHO-APT cells were serum starved for 4 hours and pretreated 
with vehicle, or 5 mM NAC for 30 minutes.  Cells were then stimulated for 5 minutes with 
vehicle, or 100 μM ATP.  Media was collected and analyzed for alkaline phosphatase 
activity.  Results are an average of three separate experiments with at least 3 replicates.  
Alkaline phosphatase activity is presented relative to the unstimulated control.  *, p < 0.001 
as compared to stimulated control.  (D) Mutant M2 CHO-APT clones, which lack functional 
TACE, were serum starved for 4 hours.  Cells were then stimulated for 5 minutes with 
vehicle, 100 μM ATP, or 10 μM of the calcium ionophore A23187 (A23).  Media was 
collected and analyzed for alkaline phosphatase activity.  Results are an average of three 
separate experiments with at least 3 replicates.  Alkaline phosphatase activity is presented 
relative to the unstimulated control.  (E)  Wild type CHO-APT cells were serum starved for 4 
hours and pretreated with vehicle, or 5 mM NAC for 30 minutes.  Cells were then stimulated 
for 5 minutes with vehicle, 100 μM ATP, or 10 μM A23187.  Media was collected and 
analyzed for alkaline phosphatase activity.  Results are an average of three separate 
experiments with at least 3 replicates.  Alkaline phosphatase activity is presented relative to 
the unstimulated control.  *, p < 0.002 as compared to A23187 stimulated control. 
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Figure 2.5  Mitochondrially-derived ROS is required for ATP-induced TGF-α shedding.  (A) 
CHO-APT cells were serum starved for 4 hours and pretreated with DMSO, or 1 mM 
apocynin for 30 minutes.  Cells were then stimulated for 5 minutes with vehicle, or 100 μM 
ATP.  Media was collected and analyzed for alkaline phosphatase activity.  Results are an 
average of three separate experiments with at least 3 replicates.  Alkaline phosphatase 
activity is presented relative to the unstimulated control.  (B) CHO-APT cells were serum 
starved for 4 hours and pretreated with DMSO, or 1 μM myxothiazol for 30 minutes.  Cells 
were then stimulated for 5 minutes with vehicle, or 100 μM ATP.  Media was collected and 
analyzed for alkaline phosphatase activity. Results are an average of three separate 
experiments with at least 3 replicates.  Alkaline phosphatase activity is presented relative to 
the unstimulated control.  *, p < 0.001 as compared to stimulated control.  (C) CHO-APT 
cells were serum starved for 4 hours and pretreated with DMSO, or 25 μM rotenone for 30 
minutes.  Cells were then stimulated for 5 minutes with vehicle, or 100 μM ATP.  Media was 
collected and analyzed for alkaline phosphatase activity.  Results are an average of three 
separate experiments with at least 3 replicates.  Alkaline phosphatase activity is presented 
relative to the unstimulated control.  *, p < 0.001 as compared to stimulated control.  (D) 
CHO-APT cells were serum starved for 4 hours and pretreated with DMSO, 5 mM NAC, or 
1μM myxothiazol and 25 μM rotenone for 30 minutes.  Cells were then stimulated for 5 
minutes with vehicle, or 100 μM ATP.  Media was collected and analyzed for alkaline 
phosphatase activity.  All Alkaline Phosphatase assays are an average of three separate 
experiments with at least three replicates and presented relative to the unstimulated control 
samples.  *, p < 0.001 as compared to stimulated control.  (E) CHO cells were serum 
starved for 4 hours then pre-treated with vehicle, or 1 μM myxothiazol and 25 μM rotenone 
for 30 minutes.  During pre-treatment, cells were also loaded with 250 nM MitoTracker Red 
and treated as described in Materials and Methods.  Cells were stimulated with vehicle, or 
100 μM ATP.  Data represents three separate experiments of at least 4 replicates relative to 
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the unstimulated control.  *, p < 0.03 as compared to the unstimulated control.  †, p < 0.001 
as compared to the stimulated control.     
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Chapter 3 
 
 
 
 
Discussion 
 
   The work presented here describes the characterization of a transactivation pathway 
consisting of purinergic G-protein coupled receptors (GPCRs) mediating the protease 
activity of TACE for TGF-α shedding and activation of EGFR signaling modules.  This 
transactivation pathway offers a physiologically relevant model to examine the mechanism 
of TACE regulation of EGF-like growth factor shedding.  I present evidence that 
mitochondrial ROS is a previously unrecognized source of ROS for the regulation of TACE-
dependent P2Y-induced shedding.  This pathway is also independent of the previously 
reported signaling intermediates Src, PKC, MAPK and intracellular calcium stores.   
 
TACE mediates P2Y-stimulated TGF-α Shedding 
   EGF-like growth factor shedding by a zinc-dependent metalloprotease is necessary for 
GPCR-stimulated EGFR transactivation.  Multiple metalloproteases have been implicated in 
this critical growth factor shedding step and specifically in TGF-α shedding (89,212,226).  
P2Y2 receptors were recently shown to activate ADAM10 and TACE activity towards 
amyloid precursor protein in astrocytoma cells (197).  To identify the metalloprotease 
responsible for P2Y-initiated TGF-α shedding and activation of EGFR, we tested TACE-
deficient cells for their ability to transactivate EGFR following ATP stimulation.  EGFR 
phosphorylation was detected after the addition of exogenous EGF, however without 
functional TACE, ATP-induced EGFR activation was not detected.  Furthermore, when we 
directly assessed ATP-induced TGF-α shedding in TACE-deficient murine cells, almost all 
shedding was lost.  We also demonstrated a requirement for TACE in TGF-α shedding from 
CHO cells using cells carrying point mutations in each TACE allele that disrupts either 
function, or folding (M2 cells) (201,202).  We showed a complete loss of TGF-α shedding in 
response to ATP stimulation in M2 cells, yet when TACE was transiently expressed in the 
M2 cells, shedding was partially restored, though not to the same extent as in wild type cells 
due to expression of TACE in a small population of cells (data not shown).  These results 
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demonstrate TACE as the major protease required for TGF-α shedding after P2Y receptor 
stimulation and confirm previous results from our lab, and many others, that TACE is the 
major sheddase for TGF-α, along with the other EGFR ligands, AR, HB-EGF, EPI and EPR 
(33,34,47,89,93,109-111,128).  The loss of EGFR transactivation in cells inhibited with 
metalloprotease inhibitor, or lacking functional TACE, also underscores the necessity of 
proteolytic processing of EGFR ligands in this pathway. 
         
P2Y Family Receptors Transactivate EGFR 
   The P2Y family of receptors binds extracellular nucleotides as hormone ligands; these 
nucleotides are released from millimolar intracellular stores in response to stress and 
stimulation (205).  The P2Y2 and P2Y4 receptors specifically respond to ATP, or UTP, while 
other P2Y receptors utilize GTP, ADP and/or UTP.  P2Y2 and P2Y4 receptors are expressed 
in muscle (smooth muscle cells), heart (cardiomyocytes), brain (astrocytes and 
astrocytomas), spleen and lung, among other tissues (205).  We show by semi-quantatative 
RT-PCR that P2Y2 receptors have elevated expression over P2Y4 receptors in murine 
fibroblast cells and confirm that CHO cells also express P2Y2, but lack P2Y4 expression; 
given the presence of an intact transactivation loop in both cell types, this suggests a 
prominent role for P2Y2 receptors as the initiator of ATP-induced EGFR transactivation.  
However, we cannot exclude a contribution by low-abundance P2Y4 receptors in the mouse 
cell line.   
   Our work reveals an alternative model to the Src-dependent intracellular signaling in P2Y-
stimulated EGFR transactivation pathways.  P2Y2 receptors have been established as 
transactivators of EGFR in rat fibroblasts, PC12 and astrocytoma cells, activating the MAPK 
pathways through EGFR-dependent signaling (206,207,225).  P2Y2–induced transactivation 
was shown to require both, intracellular calcium and PKC-dependent activation of the kinase 
CADTK (RAFTK, PYK2) for activation of EGFR in PC12 cells (206,207).  P2Y2 –dependent 
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transactivation was later shown to involve Src-dependent association between EGFR and 
P2Y2 receptors in astrocytoma cells (225).  Src can also directly phosphorylate EGFR and 
EGFR-binding proteins Shc and Grb2 (159,227), suggesting a ligand-independent activation 
model.  We examined the role of the triple membrane passing model for P2Y transactivation 
of EGFR (114).  This model was first described by Prenzel et al. (117) and utilizes 
metalloprotease activity to activate EGFR in a ligand dependent manner.  Indeed, growth 
factor shedding was increased in response to ATP and protease activity was required for 
EGFR activation.  Due to the previous emphasis on Src as an intermediate in GPCR-EGFR 
transactivation pathways, we used inhibitors to demonstrate that this pathway was 
independent of Src family tyrosine kinases.  The existence of two distinct pathways for 
EGFR transactivation, one independent and one dependent on Src activity, could allow for 
increased signal module specificity.  This idea is supported by the report that CADTK and 
Src combine to transactivate EGFR by direct phosphorylation following GPCR stimulation, 
but are not required for activation of MAPK pathways upon EGFR activation by LPA in 
mouse embryonic fibroblasts (163).  Taken together, these reports, and our work, suggest 
that EGF-like growth factor binding could be key to activating EGFR-dependent MAPK 
pathways following GPCR stimulation complementing Src-activated EGFR downstream 
pathways. 
 
Activation of TACE-mediated TGF-α Shedding Requires Mitochondrial ROS 
   Besides Src tyrosine kinases, many other distinct signaling pathways and molecules have 
been implicated in the activation of TACE-dependent shedding (120).  Since transactivation 
allows for a physiologically relevant and rapid mechanism to study the activation of TACE, 
we tested previously identified signaling pathways in this system.  We were surprised to 
discover that ATP-stimulated TACE activity is not regulated by PKC, MAPK, or intracellular 
calcium release.  Our results are similar to those found for ATP-stimulated, TACE-
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dependent APP shedding, which also did not rely on PKC, MAPK, or intracellular calcium 
(197).  However, previous results, from numerous reports in distinct cell types with each of 
these signaling molecules, suggest that there are multiple signaling schemes that lead to 
TACE-dependent shedding, based upon cell type and cell treatment. 
   Calcium is a common second messenger utilized by GPCRs (224).  Calcium can be found 
downstream of ATP signaling and is known as a key component for EGFR transactivation 
and in shedding activation schemes (123,174,199,200,204).  We have used the calcium 
ionophore A23187, which couples extracellular calcium to transport the ions through the 
membrane, independent of channels or pores, to assess the role of extracellular calcium in 
activation of shedding.  Stimulation with this reagent in wild type CHO cells led to a 
significant increase in TGF-α shedding similar to results seen with shedding of HB-EGF 
(123).  Using CHO cells lacking functional TACE (M2), A23187-induced shedding was 
markedly decreased compared to wild type cells, but still displayed a minimal increase of 
TGF-α shedding over control treated M2 cells.  This is consistent with a report that a 
different ionophore can stimulate TGF-α, HB-EGF and AR shedding in the absence of TACE 
activity (89).  Based on these results and residual shedding from mouse cells lacking TACE, 
we conclude the major sheddase for TGF-α must be TACE, but it is not the only protease 
capable of cleaving TGF-α.  The redundant activity could be important for tissues where 
TACE is not highly expressed, or cannot function due to disease or mutations. 
   Reactive oxygen species (ROS) gained increasing attention for their important role as a 
second messenger and in TACE activation.  ROS can be generated in many cell types in 
response to a host of stimuli including cytokines, growth factors and cellular stress, and are 
then utilized as signaling intermediates in redox sensitive pathways (213).  Exogenous 
addition of the ROS, hydrogen peroxide, which mimics oxidative stress, has been shown to 
stimulate shedding of TGF-α, AR, HB-EGF and EGFR activation (100,152,179,181).  ROS 
have also been identified as intermediates of GPCR-induced shedding by angiotensin II, 
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endothelin-1, phenylepherine, lipopolysaccharide and lysophosphatidylcholine 
(179,180,185,198,222).  P2Y receptors have also been tied to ROS production in 
eosinophils, prostate and thyroid tumor cells (199,200,214).  We examined the possibility 
that ROS may therefore mediate TGF-α shedding in response to ATP in our system.  Using 
the ROS scavenger NAC, we show that induced shedding is completely dependent on the 
presence of ROS in both murine and CHO cells.  This evidence supports ROS signaling as 
a requirement for induced, TACE-dependent EGF-like growth factor shedding. 
   To further examine the source of ROS acting in TACE activation, we tested the inhibitor 
apocynin in ATP stimulated cells.  The role of the NADPH oxidase (Nox) complex is a low 
level homologue of the phagocytic oxidase and one of the major sources of ROS in non-
phagocytic cells.  Using the inhibitor apocynin, which blocks formation of Nox complex, we 
found that over a range of concentrations from 30 μM to 1 mM, TGF-α shedding was 
unaffected ruling out the function of Nox in this pathway.  Thus, we have identified a 
requirement for a source of ROS, distinct from Nox, for P2Y-induced TGF-α shedding.   
   A second major source of ROS that could be utilized as a second messenger is 
superoxide anion formation as a by-product of oxidative phosphorylation in the mitochondria 
(216).  Mitochondrial ROS signaling has been implicated in cellular metabolism through JNK 
pathways (228) and linked to cardiovascular remodeling and disease, aging and cell fate 
determinations (216).  Mitochondrial ROS are also implicated in GPCR-dependent 
lysophosphatidylcholine activation of MAPK pathways (223).  It is tempting to presume this 
GPCR-stimulated activation of MAPK pathways could depend on EGFR transactivation, 
especially when considering that mitochondrial ROS can stimulate EGFR activation.  
Exogenous hydrogen peroxide added to COS-7 cells led to EGFR activation that was further 
dependent on mitochondrially-derived ROS (217).  To test for the possible role of 
mitochondrially-derived ROS in our system, we used two separate inhibitors of the electron 
transport chain to block ROS production.  Myxothiazol, which inhibits Coenzyme Q: 
76
cytochrome c oxidoreductase (Complex III), and rotenone, which inhibits NADH 
dehydrogenase (Complex I); each partially inhibited ATP-induced TGF-α shedding when 
used separately.  When added together the inhibitors completely blocked induced TGF-α 
shedding, matching the results with the non-specific scavenger NAC.  Furthermore, we 
directly measured an increase in ROS within mitochondria, which was also inhibited by 
treatment with the combination of mitochondrial protein complex inhibitors.  We offer 
evidence that P2Y receptors couple to mitochondrial ROS as a signaling intermediate for 
regulation of P2Y-induced EGFR transactivation and report for the first time that 
mitochondrial derived ROS regulates GPCR-induced growth factor shedding. 
   Our findings, implicating the mitochondria as a source of ROS following GPCR signaling, 
differ from previously reported GPCR-induced shedding results.  Stimulation with 
angiotensin II, endothelin-1, lipopolysaccharide, lysophosphatidylcholine and phenylephrine 
utilized Nox dependent ROS production for HB-EGF and TGF-α shedding 
(179,180,185,204,222,229) based on experiments that either knocked down expression of 
Nox subunits.  For P2Y-induced ROS production, use of the inhibitor diphenylene iodonium 
(DPI) implicated the cytoplasmic Nox complex (199,200).  DPI acts by binding flavoproteins 
to inhibit ROS production such as the flavoprotein cytochrome b558 in the cytoplasmic Nox 
complex.  However, DPI may also inhibit the NADP dehydrogenase complex of the 
mitochondrial electron transport chain at low concentrations, so DPI inhibition is not limited 
to Nox-mediated signaling (230).  It is also possible that Nox may complement mitochondrial 
ROS in activation of shedding depending on the intended signal. 
 
The Mechanism of ROS Signaling for the Activation of TACE-Dependent Shedding 
   The question remains as to how GPCR activation can induce increases in ROS, especially 
from the mitochondria.  The Nox complex is dependent on Rac-1 phosphorylation of several 
cytoplasmic subunits prior to complex aggregation, which allows for known GPCR signaling 
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pathways to link to Nox through Rac-1 kinase activity (187).  ROS production has been tied 
to Src, PKC and calcium signaling in certain cell systems, similar to their roles in EGFR 
transactivation (179,186,199,200).  Despite their demonstrated role in alternative 
transactivation pathways, we have ruled out a role for Src, PKC and intracellular calcium 
stores as regulators of P2Y stimulated shedding and presumably as inducers of ROS for the 
same purpose.  However, our findings that calcium ionophore induced shedding depends on 
ROS suggests that high concentrations of extracellular calcium influx may stimulate 
mitochondrial ROS production.  Mitochondrially-derived ROS has previously been shown to 
respond to changes in intracellular calcium concentrations induced by stimuli (231).  
However, we also measured residual TGF-α shedding that was independent of ROS, 
pointing to a distinct pathway for extracellular calcium-induced shedding.  These collective 
observations hint at the complexity of regulating stimulated TACE-dependent EGF-like 
growth factor shedding. 
   The underlying mechanism for ROS-dependent, TACE activation is also still undergoing 
investigation, though potential methods have been proposed.  ROS are known to mediate 
protein kinase and phosphatase activity through oxidation of thiol groups (198).  TACE is 
cytoplasmically phosphorylated in response to growth factors, serum stimulation and PMA 
treatment, on both serine and threonine residues (86,87,232).  Our work has also shown 
phosphorylation of TACE that is dependent on the presence of the cytoplasmic domain, but 
is independent of ATP stimulation.  Phospho-amino acid analysis revealed elevated serine 
phosphorylation following ATP treatment compared to tyrosine, or threonine, suggesting 
ATP may alter the residues that are modified following stimulation if not the overall level of 
phosphorylation of the protein.  Erk kinase has been reported to phosphorylate TACE on 
threonine (86,232), while Phosphatidylinositol-Dependent Kinase-1 (PDK1) has also been 
shown to phosphorylate TACE (166,232).  Both of these kinases require an activating 
phosphorylation event and thus, could be involved in pathways regulated by ROS.  
78
However, the cytoplasmic domain of TACE may not be required for regulation of TACE 
activity.  Our work demonstrates that the ATP-induced increase in shedding in TACE 
deficient CHO cells transfected with TACE lacking the cytoplasmic domain matches 
shedding in wild type transfected cells (data not shown). This is consistent with several other 
reports in which a TACE cytoplasmic deletion mutant lacking functional TACE displayed no 
changes in shedding in response to PMA and growth factor stimulation when transfected 
into murine cells (87,88).  These results suggest that TACE may be inducibly 
phosphorylated, but requires a mechanism independent of the cytoplasmic domain for 
activation of the protease domain. 
   The prodomain of TACE, which is believed to be an inhibitor of metalloprotease function 
that must be removed prior to activation, could be the key.  The prodomain inhibition has 
been shown to depend on coordination with the cysteine-rich domain to alter the native 
conformation (63).  ROS can modify cysteine thiol groups by oxidation, thus potentially 
disrupting the prodomain masking of the catalytic zinc ion.  Zhang et al. and colleagues 
(189) proposed this model after showing inhibition with a prodomain peptide that mimicked 
the native domain could be moderated by exogenous hydrogen peroxide in an in vitro 
cleavage assay.  Thus, ROS, and especially hydrogen peroxide, which can freely diffuse 
through membranes, could act directly on the TACE protein to remove the self-imposed 
inhibition by post-translational modification of cysteine thiol moieties.   
 
   We have provided evidence for the P2Y-dependent transactivation of EGFR through 
TACE-mediated shedding of TGF-α.  The P2Y family of receptors has been shown to 
function in cardiovascular remodeling and in protection of airway epithelial cells through 
mucin production (210,233).  Both of these effects have been suggested to rely on EGFR 
signaling, revealing new potential therapeutic targets for the treatment of cardiovascular 
disease and cystic fibrosis.  We have also presented novel evidence for the use of 
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mitochondrial ROS in regulating TACE-dependent shedding.  The mounting evidence for 
ROS in TACE-mediated shedding events supports the hypothesis that ROS may be the 
point of convergence for activation of TACE by many distinct pathways.  However, the 
discovery of a second source of ROS in shedding activation, independent of Nox and known 
transactivation intermediates PKC, Src and MAPK pathways foretells the complexity still 
confronting the comprehensive elucidation of TACE activation and EGFR regulation 
scheme(s).  Alternatively, use of distinct pathways by individual GPCR pathways could also 
indicate necessary levels of signaling specificity that are required for in vivo ADAM function 
and substrate selection.  Future work will focus on reconciling the usage of varying 
pathways and signaling molecules in different cell types and for different substrates.  The 
differences between sources of ROS and the identification of the proximal signaling events 
required for induced ROS production will also be important, as these appear to be key 
intermediates in the activation of TACE-dependent shedding. These improvements in our 
understanding of TACE regulation mechanisms is the current focus of this field with the 
hope that each advance in our knowledge of TACE-dependent shedding brings us closer to 
understanding and development of novel treatments for any number of diseases.  
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